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Poly-ubiquitination is a type of post-translational modification that usually 
targets proteins for proteasomal degradation. This typically occurs when 
ubiquitin chains are linked via K48 conjugation. However, when 
polyubiquitination occurs via K63, the ubiquitin-modified protein is often not 
acted upon by the proteasome. Amongst the diverse proteasome-independent 
roles that K63-linked ubiquitination fulfils, I am especially interested in its 
involvement in protein aggregation and mitochondria clearance. In this thesis, 
I sought to clarify the role of this non-canonical form of ubiquitination in 
protein and mitochondrial homeostasis. In the first part of the thesis, I have 
provided evidence to show that during proteasome dysfunction, K63-
polyubiquitination is enhanced and that parkin is a key enzyme involved. 
Mechanistically, this phenomenon occurs as a result of increased affinity of 
parkin for Ubc13 (an E2 that mediates K63-polyubiquitination exclusively), 
which appears to facilitate the autophagic clearance of substrates and as such 
promotes cellular survival in times of proteolytic stress. In part 2 of this thesis, 
I showed that K63-linked ubiquitination can participate in mitochondrial 
homeostasis by stabilizing the expression of a cleaved form of PINK1 
(PINK1-53) which is otherwise rapidly degraded. Notably, I have also 
identified a novel pathway, i.e. TRAF6-related NF-κB pathway that is 
involved in PINK1-53 stabilization. Importantly, PINK1-53 leads to non-
selective mitochondria clearance, which may protect cells against the build-up 
of reactive oxygen species. Taken together, the results presented in this thesis 
illustrate the functional role of K63-linked ubiquitination and the mechanism 
 vi 
 
by which it maintains protein and mitochondria homeostasis in times of 
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CHAPTER 1:  INTRODUCTION 
 
1.1 Overview  
The highly conserved 76 amino acid-containing ubiquitin protein was isolated 
way back in 1975 and as the name suggests, was found to be widely expressed 
in all tissues and in all eukaryotic species (Goldstein et al., 1975). However, 
its function was not elucidated until the 1980s when it was purified as part of a 
newly discovered ATP-dependent protein degradation system, which is now 
known as the Ubiquitin Proteasome System (UPS) (Ciehanover et al., 1978) . 
This seminal discovery of ubiquitin-mediated protein degradation by Drs. 
Aaron Ciechanover, Avram Hershko and Irwin Rose, who were jointly 
awarded the Nobel Prize in Chemistry in 2004, has led the community to 
embark on an exciting journey to understand the complex biology of protein 
ubiquitination, and the cellular processes it regulates. In this thesis, I described 
my effort to characterize the role of an interesting form of ubiquitin 
modification known as K63-linked polyubiquitination in protein and 
mitochondrial homeostasis, the aberration of which is known to lead to several 
human diseases, including neurodegenerative diseases. 
 
1.2 Protein ubiquitination and degradation 
Ubiquitination is a process by which proteins are covalently tagged with a 
chain of ubiquitin, which usually targets the protein for proteasomal 
degradation (Fig. 1.1A, B). This process involves the sequential actions of 3 





- E1: the ubiquitin-activating enzyme that charges the ubiquitin 
molecule by catalyzing the formation of an E1-Ubiquitin thioester 
bond between the C-terminal glycine carboxyl group of ubiquitin and 
the active-site cysteine of E1 in an ATP-dependent reaction,  
 
- E2: the ubiquitin-conjugating enzyme which ubiquitin is transferred to 
(from E1) via the formation of an E2-Ubiquitin thioester linkage, and  
 
- E3: the ubiquitin–ligating enzyme which interacts with E2 and the 
protein substrate and in so doing brings them together into close 
proximity to allow the transfer of the ubiquitin molecule to the 
substrate. This reaction requires the conjugation of the C-terminal 
glycine carboxyl group of ubiquitin to a ε-amino group of a lysine 
residue on the protein substrate to form an isopeptide bond. It is 
noteworthy to point out that depending on the type of E3 involved; the 
process by which the ubiquitin is transferred to the substrate differs. In 
a HECT (Homologous to the E6-AP C-Terminus) domain-containing 
E3, the ubiquitin is first transferred onto the E3 via a thioester bond 
formation before being conjugated to the substrate. In a RING (Really 
Interesting New Gene) domain-containing E3, the ubiquitin is directly 
transferred from the E2 to the substrate without the formation of a 







The above sequence of catalytic events is repeated several times to allow the 
formation of a polyubiquitin chain on the substrate. During the process, the C-
terminal glycine of another ubiquitin is successively conjugated to the 
preceding ubiquitin at the ε-amino group of a free lysine residue. In most 
cases, lysine 48 on the substrate-bound ubiquitin is utilized and the resulting 
modification is known as G76-K48-linked (or simply K48-linked) 
ubiquitination (Fig. 1.1B). Proteins (mostly short-lived or misfolded proteins) 
tagged with K48-polyubiquitin chains are targeted to the 26S proteasome for 
degradation (Chau et al., 1989; Hershko and Ciechanover, 1998).  
 
Figure 1.1: Ubiquitin-proteasome system. (A) Illustration of the process of 
ubiquitination. A RING family E3 is illustrated here. S, substrate; Ub, ubiquitin (B) 
Diagram depicting the attachment of the C-terminal carboxyl group at amino acid 76 
to the ε-amino group of lysine 48 of the preceding ubiquitin. (C) Diagram showing 





Studies have shown that a chain length of 4 ubiquitin monomers or more are 
required for the proteasome to recognize the substrate for degradation 
(Thrower et al., 2000). Presumably, this requirement of a threshold length of 
ubiquitin chain will help prevent unintended protein degradation from 
occurring. 
 
The 26S proteasome is a large multi-subunit protease complex consisting of a 
barrel-shaped 20S proteolytic core flanked at one or both open ends by a 19S 
regulatory cap (Fig. 1.1C). The 20S complex is composed of 4 heptameric 
rings stacked above one another: 2 identical outer α rings and 2 identical inner 
β rings with 7 distinct subunits in each ring. The α  subunits provide binding 
sites for the 19S cap while 3 of the β subunits, β1, β2 and β5 possesses caspase-
like, trypsin-like and chymotrypsin-like activities respectively.  
 
The 19S regulatory cap (PA700) structure is divided into a base and a lid 
which is proximal and distal respectively to the 20S complex. It is required for 
substrate recognition, unfolding and translocation into the 20S complex. The 
lid is composed of 10 subunits of which the function of only 1 subunit, i.e. 
Rpn11, also known as Poh1 in humans, is known. Rpn11 is a deubiquitinating 
enzyme which cleaves the ubiquitin chain proximal to the substrate, thus 
releasing the entire chain during substrate insertion into the proteasome core. 
This process is required for proteasome-mediated protein degradation although 
the rationale behind it is still unknown. An assumption is that this process 
helps to recycle ubiquitin monomers. The base of the 19S regulatory complex 





ubiquitin binding subunits, Rpn10 and Rpn13 which recognize ubiquitinated 
substrates and 6 unique ATPase subunits required to unfold the substrate and 
allow entry into the narrow channel of the 20S proteolytic core (Finley, 2009; 
Huang and Figueiredo-Pereira, 2010).  
 
1.3 Atypical ubiquitin chains  
Although K48-polyubiquitination is universally known as the classical form of 
protein ubiquitination, it is by no means the only form. A close inspection of 
the ubiquitin sequence will reveal six other lysine residues (K6, K11, K27, 
K29, K33, and K63) on the molecule that in theory could also be utilized in 
the assembly of a polyubiquitin chain. Indeed, polyubiquitination involving all 
these non-48 lysine residues have been demonstrated (Peng et al., 2003). This 
includes the non-canonical K63-linked ubiquitination, which is the focus of 
my thesis. On top of this, monoubiquitination and multiple 
monoubiquitination of substrates have also been described. Notably, both 
K63-linked polyubiquitination and monoubiquitination of proteins are not 
typically associated with proteasome-mediated degradation but are thought to 
sub-serve other cellular roles. To complicate matters further, a ubiquitin chain 
of a different type can also emanate from a polyubiquitin chain of another type 
to result in fork linkages (i.e. mixed linkages) (Kim et al., 2007). More 
recently, a completely new form of ubiquitin linkage known as liner 
ubiquitination where ubiquitin monomers are conjugated via G76-M1 in a 
head to tail has also been described (Kirisako et al., 2006). Thus, there is a 
multitude of possibilities by which ubiquitin modification can take place, 





that easily rivals protein phosphorylation. Given this, it is interesting to ask 
what tells the cell to mediate a particular type of ubiquitin linkage. 
 
Although the factors that determine the choice of a particular form of ubiquitin 
chain linkage remains unclear, recent studies have suggested that the nature of 
E2s and E3s and their combinations influence the type of ubiquitin chains 
being formed (Ikeda and Dikic, 2008; Kim et al., 2007; Peng et al., 2003). It is 
also likely that post-translational modification of E3s and the subcellular 
compartmentalization of E2 and E3 pairs would determine the topology of 
ubiquitin chain. Unsurprisingly, different types of ubiquitination have been 
reported to serve different functions. As the different types of ubiquitination 
and their involvement in various cellular processes are too diverse to discuss 
in detail and beyond the scope of this thesis, their respective roles are briefly 
summarized in Table 1. The function of K63-polyubiquitination which is the 
topic of interest will be discussed in more detail in subsequent sections.    
Table 1: Types of ubiquitination and their respective cellular processes 
Types of 
ubiquitination  
Cellular processes  Reference 
Mono Endocytosis 
DNA repair  
(Haglund et al., 2003) 
(Hoege et al., 2002) 
K6 DNA replication and repair (Morris and Solomon, 
2004) 
K11 Endoplasmic reticulum associated 
degradation (ERAD)  
Cell cycle control  
(Xu et al., 2009) 
 
(Wickliffe et al., 2011) 
K27 NF-κB signaling 
Immunity  
(Arimoto et al., 2010) 
(Peng et al., 2011) 
K29 Lysosomal degradation  
Wnt/β-catenin signaling  
(Chastagner et al., 2006) 
(Fei et al., 2013) 
K33 T cell receptor signaling   (Huang et al., 2010) 
Linear NF-κB signaling (Rahighi et al., 2009) 
K11/K63 Endocytosis 
NF-κB signaling  
(Boname et al., 2010) 
(Dynek et al., 2010) 







1.4 K63-linked ubiquitination 
Among the alternative ubiquitin linkages, K63-polyubiquitination is by far the 
most studied modification. In 1994, the first atypical ubiquitin chain, i.e. K63 
polyubiquitin chain, was identified in Saccharomyces cerevisiae, albeit 
indirectly, through the use of ubiquitin mutants such as K63R ubiquitin, which 
allows the formation of all ubiquitin chains except K63-linked chains, and 
K63 ubiquitin, which supports only K63-linked chains (Fig. 1.2).  
 
Figure 1.2: Ubiquitin mutant constructs. Illustration showing the different types of 
ubiquitin mutant constructs frequently used in experiments. The 7 lysine residues (K) 
and its amino acid position are showed in the wild type (WT) ubiquitin construct. The 
corresponding lysine (K) to arginine (R) mutation in the various ubiquitin mutants 
constructs and the possible types of ubiquitin chains formed are as depicted.    
 
Interestingly, when K63-polyubiquitination was prevented, the survivability of 
the mutant yeast cells was dramatically reduced especially in the presence of 
various cellular stresses (Arnason and Ellison, 1994). This phenomenon 
occurs in the yeast without protein turnover being apparently affected, 
suggesting that K63-linked ubiquitination-mediated protection is independent 
of the proteasome. Supporting this, a year later, using the same S. cerevisiae 
system, the laboratory of Finley showed that K63R ubiquitin mutant (i.e. 
which cannot mediate K63-polyubiquitination) inhibits DNA repair instead of 





unlike K48-polyubiquitination which directs proteins to the proteasome for 
degradation, K63-polyubiquitination promotes cell survivability in a manner 
that is uncoupled from the proteasome. Subsequently, various independent 
studies demonstrated that K63-linked ubiquitination is involved in a wide 
range of cellular processes including endocytosis of plasma membrane 
proteins (Galan and Haguenauer-Tsapis, 1997) such as nerve growth factor 
receptor (Geetha et al., 2005), dopamine transporter (Vina-Vilaseca and 
Sorkin, 2010) and MHC class 1 protein (Duncan et al., 2006), post-replicative 
DNA repair (Hofmann and Pickart, 1999; Mailand et al., 2007; Motegi et al., 
2008), mitochondria DNA inheritance (Fisk and Yaffe, 1999), NF-κB 
signaling (Deng et al., 2000; Wertz et al., 2004), p38/JNK signaling (Tao et 
al., 2009), cell cycle regulation (Vong et al., 2005) and ribosomal function 
(Spence et al., 2000). Adding to this list is the demonstration by our lab that 
K63-linked ubiquitination serves as a cargo recognition signal for autophagy 
(Tan et al., 2008b). More recently, K63-linked ubiquitination has also been 
implicated in mitophagy (Geisler et al., 2010), a specialized form of autophagy 
where damaged mitochondria are degraded (Narendra et al., 2008). 
Collectively, these studies further strengthen the notion that K63-linked 
ubiquitination is independent of the proteasome.  
 
Structurally, K63- and K48- linked ubiquitination are distinct from each other, 
with the former existing in an extended conformation mirroring a string of 
beads whereas the latter adopt a closed and more compact conformation (Datta 
et al., 2009; Tenno et al., 2004; Varadan et al., 2004). This structural 
difference between K63 and K48-linked ubiquitin chains may provide a 





Notwithstanding the above, a few reports have suggested that K63-
polyubiquitination might tag proteins to the proteasome and promote its 
degradation (Hofmann and Pickart, 2001; Kim et al., 2007; Saeki et al., 2009). 
Most of these studies were done in vitro, although Saeki et. al. was able to 
show in cultured cells that the substrate Mga2-p120 containing high levels of 
K63-polyubiquitination is targeted to the proteasome for degradation (Saeki et 
al., 2009). However, the demonstration that K63-polyubiquitination is 
functionally analogous to its structurally different K48-linked counterpart (i.e. 
in the context of targeting substrates for proteasomal degradation) is 
intriguing. It would also suggest that in the presence of proteasome 
impairment, K48- and K63- linked ubiquitination would increase to a similar 
extent. This is however not the case as mass spectrometry data from cultured 
cells showed that all types of polyubiquitin chains increased in the presence of 
acute proteasome inhibition except those that are K63-linked (Jacobson et al., 
2009; Xu et al., 2009), supporting the notion that K63-polyubiquitination is 
uncoupled from the proteasome. This is further supported by recent findings 
that although K48- and K63-linked ubiquitin chains bind with equal affinity to 
the proteasome in vitro, the ratio of K48/K63 bound to the proteasome inside 
the cell is significantly more as 1) K63-linked ubiquitin chains are rapidly de-
ubiquitinated to monoubiquitin by the Rpn11, a proteasomal lid deubiquitinase 
subunit, and Uch37 and Usp41, both of which are deubiquitinating enzymes 
that associate with the proteasome. This reduces its substrate affinity for the 
proteasome (Jacobson et al., 2009), 2) K63 ubiquitin chains are bound to 
soluble factors in cells e.g., NEMO (Jacobson et al., 2009) or ESCRT0 





cellular factor like hRad23B binds specifically to K48-linked ubiquitin chain 
and promotes its binding to the proteasome (Nathan et al., 2013). These 
scenarios provide a plausible explanation for the discrepancies obtained from 
in vivo and in vitro results. It also strongly suggests that different cellular 
factors might bind to different ubiquitin chains and thereby affecting or 
determining the function of the ubiquitin chain and the fate of the 
ubiquitinated substrate. Despite the controversies, there is now a general 
acceptance by the community that K63-polyubiquitination is uncoupled from 
the proteasome, although it is impossible to exclude the possibility that a small 
subset of K63-polyubiquitinated substrates might indeed be degraded by the 
proteasome.          
 
1.4.1 Components involved in K63-polyubiquitination  
As mentioned earlier, the type of E2s, E3s and E2 and E3 pairs are important 
determinants of the nature of the ubiquitin linkage formed. Relevant to this is 
that Ubc13 (in association with either of the E2 variants, Uev1a or Mms2) is 
the only E2 known to date to mediate K63-polyubiquitination. Thus, K63-
linked ubiquitination in whatever cellular context will necessarily involve the 
participation of this unique E2. 
 
The crystal structure of the Ubc13/Mms2 heterodimer has been described and 
it revealed the intriguing mechanism by which K63-polyubiquitination occurs. 
Ubc13, the catalytic subunit of the heterodimer, binds to a free ubiquitin 
(donor ubiquitin) in a manner that directs the C-terminal Glycine (G76) of 





ubiquitin bound to a substrate (preceding ubiquitin) and positions K63 of the 
ubiquitin to the active site of Ubc13. This places G76 of the donor ubiquitin 
within 3Å of K63 of the preceding ubiquitin, thus mediating K63-linked 
ubiquitination (Fig. 1.3) (McKenna et al., 2001; VanDemark et al., 2001).  
 
Figure 1.3: Ubc13/Mms2 mediates K63-linked ubiquitination. Diagram depicts 
the mechanism in which Ubc13/Mms2 mediates K63-linked ubiquitination. Ubc13 
binds to free donor ubiquitin and directs the C-terminal carboxyl group to its active 
site. Mms2 binds to the preceding ubiquitin and presents the ε-amino group of K63 to 
the active site. This places the C-terminal G76 within 3Å of K63 of the preceding 
ubiquitin, thus mediating K63-polyubiquitination.      
 
This model supports the observation that E1 together with Ubc13 and its 
variant is able to mediate K63-polyubiquitination in the absence of E3s 
(Hofmann and Pickart, 1999). In accordance, any E3s that partners Ubc13 and 
Uev1 or Mms2 would be able to mediate K63-linked ubiquitin chains on its 
substrate. In other words, Ubc13/Uev1a or Mms2 determine ubiquitin 
topology while the E3s provide substrate specificity. 
 
In contrast to the rarity of E2s mediating K63-polyubiquitination, several E3s 
have been reported to be associated with this mode of ubiquitination (Table 2). 
Among these is the RING-containing parkin, which is of significant interest to 
the community as its mutation is associated with a familial form of 





(ARJP) (Kitada et al., 1998). Interestingly, unlike many of its counterparts, 
parkin is a multifunctional E3 capable of mediating both K63-
polyubiquitination (Doss-Pepe et al., 2005; Lim et al., 2005) and K48-
polyubiquitination (Shin et al., 2011; Wang et al., 2011a). In additional to 
these, parkin can also mediate monoubiquitination (Hampe et al., 2006; 
Matsuda et al., 2006). This multifunctionality makes parkin a highly versatile 
E3 that is able to promote both proteasomal-dependent and -independent 
ubiquitination, although the context of which it selects the ubiquitination type 
was not clear (Note: We have since provided some clarifications on this, the 
results of which are presented in Chapter 3 of this thesis). It is noteworthy to 
mention that our lab is particularly interested to understand the biology of 
parkin, especially on its role in Parkinson’s disease. A discussion on parkin 
can be found in section 6 of this chapter. Besides parkin, several other E3 
ligases have also been reported to partner with Ubc13 to mediate K63-
polyubiquitination. These include a related RING domain-containing E3 
member known as TRAF6, whose self-ubiquitination via K63 is important for 
the recruitment of components necessary for NFB-linked signaling (Deng et 
al., 2000). Another of these is CHIP, which like parkin is also capable of 
forming K48-linked or K63-linked ubiquitin chains by switching between its 
E2 partners, UbcH5a and Ubc13/UeV1a. Other known E3 mediators of K63-









Table 2: Ubiquitin enzymes associated with K63-polyubiquitination 
Enzyme  Selected substrate Cellular processes Reference 
E3    




(Zhang et al., 2005) 





(Henn et al., 2007; 
Lim et al., 2005; 
Olzmann et al., 
2007) 
   UCHL1 α-synuclein Protein QC (Liu et al., 2002) 
   Nedd4-2 Dopamine transporter Endocytosis (Vina-Vilaseca and 
Sorkin, 2010) 
   SHPRH PCNA DNA repair (Motegi et al., 2008) 
   HLTF PCNA DNA repair (Motegi et al., 2008) 
   RNF8 Histone H2A/X DNA repair  (Mailand et al., 
2007) 
   TRAF6 NEMO NF-κB signaling (Deng et al., 2000) 
   TRAF2 RIP NF-κB signaling (Wertz et al., 2004) 
   ITCH RIP2 P38/JNK signaling  (Tao et al., 2009) 
   March5  TANK  Toll-like receptor 
signaling  
(Shi et al., 2011) 
   Ufd1 Survivin Cell cycle control (Vong et al., 2005) 
   RNF185 BNIP1 Mitophagy (Tang et al., 2011) 
 
DUB 
   
   CYLD TRAF2,TRAF6, 
NEMO 
NF-κB signaling (Kovalenko et al., 
2003; Trompouki et 
al., 2003) 
   A20 TRAF6 NF-κB signaling (Wertz et al., 2004) 
   Ataxin-3 ERAD substrate eg. 
(TCRα)  
Protein QC (Wang et al., 2006; 
Winborn et al., 2008) 
   AMSH EGF receptor  Endocytosis (Sato et al., 2008) 
 
1.4.2 Deubiquitination of K63-linked chains 
Like phosphorylation and dephosphorylation, ubiquitin modifications are also 
reversible. As briefly mentioned earlier, ubiquitin chains can be hydrolyzed by 
a class of enzymes known as deubiquitinating enzyme (DUB). The list of 
DUBs capable of removing K63-linked ubiquitin chains are shown in Table 2. 
These include A20 and CYLD, both of which are potent inhibitors of NFB 
signaling (Kovalenko et al., 2003; Trompouki et al., 2003; Wertz et al., 2004), 
and ataxin-3, a DUB associated with Spinocerebellar Ataxia type 3, a 





ataxin-3 binds to both K48- and K63-linked chains, but preferentially cleaves 
the latter chain type (Winborn et al., 2008). This is an interesting function that 
has implications on the half-life of K63-linked chains. It is conceivable that 
through such a linkage-specific hydrolyzing function, ataxin-3 can potentially 
influence the biology of proteins modified by K63-linked ubiquitination.  
 
From the myriad of E3 ligases and DUBs involved, one could immediately 
infer that ubiquitin modifications (not just K63-linked chains) on a protein are 
unlikely to represent static tags, but instead are dynamic signals that could be 
edited and at times, remodeled, as is being recognized currently (Crosas et al., 
2006; Hanna et al., 2006). 
 
1.5 K63-linked ubiquitination and protein homeostasis 
Among the diverse cellular processes that K63-linked ubiquitination is 
involved in, we are specifically interested to understand its role in protein and 
mitochondrial homeostasis because failure in these quality control (QC) 
mechanisms are thought to contribute to neurodegeneration, a topic that 
represents the primary interest of the lab. Relevant to the mechanics of cellular 
protein homeostasis is the concept of aggresome formation and its clearance 
by autophagy, which are discussed below. How K63-linked ubiquitination 







1.5.1 Aggresome formation and clearance 
The cell possesses complex QC mechanisms to ensure that proteins are 
maintained in their functional state, repaired if unfolded or degraded when 
they are beyond repair. Proteins may also be removed after they have fulfilled 
their function; the speed of which they are turned over depends on their 
respective half-life. In essence, the “life cycle” of a protein can be divided into 
3 major phases: synthesis, functional and degradation. In the first phase, 
newly synthesized proteins aided by chaperones are folded into their native 
state. If this fails, which happens occasionally, misfolded proteins with their 
hydrophobic surfaces exposed might aggregate with one another, rendering 
them non-functional. Moreover, the accumulation of aggregated proteins can 
potentially interfere with cellular processes. Thus, misfolded proteins need to 
be cleared in a timely fashion. Current knowledge indicates that misfolded 
proteins are typically ubiquitinated by K48-linked ubiquitin chains, which 
directs them to the proteasome for degradation (Liberek et al., 2008). 
However, in instances of cellular stress, the balance between the generation 
and clearance of misfolded proteins might be tilted in such a way that the cell 
becomes overwhelmed with misfolded proteins. In such circumstances 
(especially under conditions of proteasome impairments), another QC 
mechanism, i.e. autophagy, comes into play.  
 
To facilitate this alternative degradation process, misfolded proteins are 
delivered to the perinuclear region via the actions of HDAC6, an ubiquitin 
binding protein, and dynein, a molecular motor that is involved in retrograde 





aggregates though its BUZ domain and acts as an intermediate binding partner 
which links the ubiquitinated proteins to dynein (Kawaguchi et al., 2003). 
Dynein then transports the cargo in a retrograde fashion along microtubules to 
the microtubule organizing center (MTOC) that is juxtaposed to the nucleus, 
forming an aggresome (Johnston et al., 2002; Johnston et al., 1998). It was 
postulated that aggresomes serve as an inert storage center for misfolded 
proteins and a centralized region to facilitate lysosomal recruitment (Lee et al., 
2010a) and thereby autophagy (Kopito, 2000). Supporting this, studies have 
showed that autophagy is enhanced in the presence of proteasome inhibition, 
suggesting a compensatory mechanism to degrade the misfolded proteins 
(Iwata et al., 2005; Pandey et al., 2007). Various groups including ours have 
also shown in cultured cells exposed to proteasome inhibitor that aggregation-
prone proteins frequently accumulate in aggresome-like structure, which could 
then be cleared by autophagy activation. Moreover, the inhibition of 
autophagy increases the incidence of protein aggregation (Iwata et al., 2005; 
Opazo et al., 2008; Wong et al., 2008). Thus, in the presence of proteolytic 
stress, the cell evidently possesses a compensatory mechanism that promotes 
the accumulation of misfolded proteins into an inert structure and importantly, 
their subsequent clearance by autophagy.   
 
1.5.2 Autophagy   
The process of autophagy is highly regulated, consisting of 6 steps, 1) 
autophagy induction, 2) vesicle nucleation, 3) vesicle elongation, 4) vesicle 
maturation, 5) vesicle fusion with lysosome and 6) degradation of vesicular 
contents (Fig. 1.4A). The induction of autophagy is regulated by numerous 





input into mTOR (mammalian target of rapamycin), the main negative 
regulator of autophagy (Fig. 1.4B).   
 
Figure 1.4: Schematic diagram of autophagy. (A) Diagram showing the process of 
autophagy and the relevant proteins that are involved. Upon autophagy induction, 
PI3K consisting of Beclin-1, Vsp34, mATG14 and p150 initiates vesicle nucleation at 
the phagophore assembly site. This recruits ATG12-ATG15-ATG16 complex which 
promotes LC3-II localization to the site. LC3-II then mediates the elongation of the 
phagophore into a double membrane vesicle known as an autophagosome. Upon 
autophagosome formation, ATG12-ATG5-ATG16 complex dissociates from the 
autophagosome and LC3-II localized on the outer membrane is cleaved by ATG4 to 
LC3-I. The autophagosome then fuses with lysosome forming autolysosome. The 
acidic lysosomal contents are then released into the autolysosome, degrading the 
contents and the inner membrane of the autophagosome. (B) Diagram demonstrating 
the induction of autophagy. The AMPK pathway inhibits the negative regulator of 
autophagy, mTOR thus activating autophagy while the AKT and ERK pathways 
inhibit autophagy. mTOR inhibits autophagy via the phosphorylation and inactivation 
of ULK1 and ATG13. When mTOR is inhibited, mTOR dissociates from the ULK1-
ATG13-FIP200 complex, thus relieving its inhibition on ULK1. Activated ULK1 and 
ATG13 induce autophagy. (C) Diagram showing the formation of ATG12-ATG5-
ATG16 complex and LC3-II. ATG12-ATG5 complex is formed by the sequential 
action of ATG7 (E1-like) and ATG10 (E2-like), after which it is coupled to ATG16, 
forming ATG12-ATG5-ATG16 complex. In another reaction, LC3 is cleaved by 
ATG4 to LC3-I. LC3-1 is then coupled to phosphatidylethanolamine by ATG7 and 






In an activated state, mTOR binds to and inhibits ATG13-ULK1-FIP200 
complex, a complex that induces autophagy. It does so by phosphorylating 
ULK1 and hyperphosphorylating ATG13. This inhibits ATG13 and partially 
inhibits ULK1, thus inhibiting autophagy as a consequent. In an inhibited 
state, mTOR dissociates from the ATG13-ULK1-FIP200 complex, thereby 
relieving its inhibition on ATG13 and ULK1 to allow the induction of 
autophagy (Fig. 1.4B) (Jung et al., 2009). The activated ATG13-ULK1-
FIP200 complex initiates vesicle nucleation by promoting the recruitment of 
further downstream autophagy components to a phagophore assembly site 
(PAS) (Cheong et al., 2008). Vesicle nucleation involves the activity of a class 
III phosphatidylinositol 3-kinase (PI3K) complex which consists of Vps34, 
beclin-1, myristylated kinase p150 and mATG14. This complex converts 
phosphatidylinositol (PtdIns) to phosphatidylinositol-3-phosphate (PtdIns3P) 
(Kihara et al., 2001; Liang et al., 1999; Sun et al., 2008). PtdIns3P serves as an 
essential signal for the recruitment of downstream effectors of autophagy. 
These downstream effectors induce the formation of a phagophore and its 
elongation to a double membrane vesicle known as autophagosome (Obara et 
al., 2008). The elongation of the phagophore requires two ubiquitin-like 
conjugation systems (Fig. 1.4C). In one of the system, ATG7 (E1-like) and 
ATG10 (E2-like) catalyze the conjugation of ATG12 and ATG5 (Mizushima 
et al., 1998). ATG12-ATG5 complex then interacts with ATG16 and attaches 
itself to the phagophore (Mizushima et al., 2003). In the other system, LC3 is 
cleaved rapidly by ATG4 to LC3-I (Kirisako et al., 2000). LC3-I is then 
conjugated to phosphatidylethanolamine (PE) on the phagophore membrane 





complex, forming LC3-II (Hanada et al., 2007; Ichimura et al., 2000). Upon 
autophagosome maturation, ATG12-ATG5-ATG16 dissociates from the 
vesicle (Mizushima et al., 2003). Outer membrane LC3-II are cleaved by 
ATG4 and returned to the cytosol while inner membrane LC3-II remains 
attached (Kabeya et al., 2000; Kirisako et al., 2000). The autophagosome then 
fuses with lysosome forming autolysosome, during which the acidic lysosomal 
contents are released into the autolysosome. This degrades the autophagosome 
contents and the inner membrane of the autophagosome. 
 
1.5.3 Role of K63 polyubiquitination in the formation and autophagic 
clearance of aggresomes 
Autophagy was once viewed as a nonselective degradation process that 
degrades organelles and proteins enclosed by autophagosome. However, in 
recent years, numerous studies have shown the existence of selective 
autophagic degradation of various cellular structures including protein 
aggregates and mitochondria (Xie and Klionsky, 2007). So, how does a 
seemingly non-specific formation and elongation of the phagophore lead to 
the selective degradation of aggregates? One of the possible ways as 
discussed above would be to concentrate misfolded proteins to aggresome, 
with the aid of HDAC6, which could then recruit the autophagic machinery to 
clear the aggresome formed. Significantly, two other ubiquitin binding 
proteins, p62 and NBR1 (neighbor of BRCA1 gene 1) have been found to 
mediate selective autophagy. These proteins, besides binding to ubiquitin via 
their respective ubiquitin-association (UBA) domain also bind to LC3 through 





ubiquitinated proteins to the autophagic machinery (Kirkin et al., 2009a; 
Komatsu et al., 2007; Pankiv et al., 2007).  
 
Interestingly, all three ubiquitin-binding proteins, i.e. HDAC6, p62 and NBR1, 
which are involved in selective autophagy bind preferentially to proteins that 
are ubiquitinated via K63-linked chains, suggesting that K63-
polyubiquitination may serve as a marker that targets misfolded proteins to the 
autophagic machinery (Kirkin et al., 2009a; Olzmann et al., 2007; Seibenhener 
et al., 2004; Tan et al., 2008a). Supporting this, our lab has previously 
demonstrated that K63-linked ubiquitination is required for the formation and 
clearance of inclusions via autophagy (Tan et al., 2008b). We found that in the 
presence of proteasome inhibition, ubiquitin-positive inclusions formed in 
cultured cells expressing either Ubc13/Uev1a or K63 ubiquitin mutant (both 
promotes K63-linked ubiquitination) could be cleared by autophagy 
activation, whereas those formed in the presence of K63R ubiquitin mutant 
(which prevents K63-polyubiquitination) or UbcH7 or UbcH8 (which are not 
associated with K63-linked ubiquitination) were not amenable to autophagic 
clearance (Tan et al., 2008a; Tan et al., 2008b). Moreover, K63-positive 
inclusion, but not K63-negative inclusions, are frequently colocalized with 
LAMP-2A, a lysosomal marker, suggesting that K63-linked ubiquitination 
recruits lysosomal machinery to the inclusions for autophagic clearance 
(Kirkin et al., 2009b; Olzmann et al., 2007; Tan et al., 2008b). Taken together, 
the results above suggest that cells might favor K63-linked ubiquitination 
under proteolytic stress to direct misfolded proteins to an inert structure 





was largely unknown, although one could assume that Ubc13 and its partner 
E3 will be involved. Among the E3s capable of mediating K63-linked 
ubiquitination, parkin is particularly attractive in this context. 
 
1.6 Parkin-mediated K63-linked ubiquitination and protein homeostasis 
As mentioned earlier, our lab is particularly interested in gaining a better 
understanding of parkin function among the spectrum of E3 members known 
to mediate K63 ubiquitination. In the following sections, I shall provide a brief 
overview of parkin and its role in protein homeostasis. 
 
1.6.1 Parkin and Parkinson’s disease 
Parkinson’s disease (PD) is a prevalent neurodegenerative movement disorder 
affecting millions of predominantly elderly individuals worldwide. Clinically, 
the disease is attended by a constellation of motoric deficits including 
bradykinesia (slowness in movements), rigidity and tremor that are 
collectively referred to as “Parkinsonism”. The principal neuropathology that 
gives rise to these characteristic motor phenotype of PD patients is the rather 
selective loss of midbrain dopaminergic (DA) neurons in the substantia nigra 
pars compacta (SNpc), which results in a severe depletion of striatal dopamine 
and thereby an impaired nigrostriatal system that otherwise allows an 
individual to execute proper, coordinated movements. This specific pattern of 
neurodegeneration in PD is often accompanied by the presence of eosinophilic 
intracytoplasmic inclusions known as Lewy bodies (LBs) in surviving neurons 
in the SNpc as well as in other affected brain regions (Braak et al., 2003). 





attributed to mutations in specific genes, which includes α-synuclein, parkin, 
DJ-1, PINK1, and LRRK2 (Bonifati et al., 2003; Gaig et al., 2007; Kitada et 
al., 1998; Polymeropoulos et al., 1997; Valente et al., 2004). The clinical 
manifestation and pathology of these familial forms of PD can often be quite 
indistinguishable from the more common sporadic PD cases, which fuelled the 
widely-held assumption that a better understanding on how these genes go 
awry during the disease process may shed light onto the pathogenesis of 
sporadic PD.  
 
Mutations in parkin were originally identified in Japan more than a decade ago 
to be causative of autosomal recessive juvenile parkinsonism (Kitada et al., 
1998). Following this discovery, several ethnically diverse individuals with 
early-onset PD (age < 45 years) in other parts of the world were also found to 
carry parkin mutations, which occur at a frequency of about 10-20% and 50% 
in sporadic and familial early-onset cases respectively (Lucking et al., 2000; 
Mata et al., 2004; Periquet et al., 2003). To date, more than 100 different 
disease-associated parkin mutations have been described with over 50 of these 
being missense/nonsense substitutions. Interestingly, post-mortem studies 
(albeit limited) revealed that the majority of parkin-related cases are devoid of 
classical LBs (Hayashi et al., 2000; Mori et al., 1998; Pramstaller et al., 2005), 
suggesting that parkin-associated parkinsonism is pathologically distinct from 
idiopathic PD, and as such may represent a phenocopy of the latter. However, 
this is debatable as LBs are found in at least two cases of parkin-related PD 





that functional parkin may facilitate LB formation, which we favor as a 
working hypothesis.  
 
1.6.2 Parkin and K63-linked ubiquitination 
Structurally, the 465 amino acid-containing human parkin protein is comprised 
of an ubiquitin-like (UBL) domain at its N-terminus, a RING1-IBR-RING2 
domain at its C-terminus and a RING0 domain that links the two domains 
(Fig. 1.5) (Riley et al., 2013). 
 
Figure 1.5: Schematic diagram of parkin. The respective domains present in parkin 
are indicated. UBL, ubiquitin-like domain; RING, Really interesting new gene; IBR, 
In-between-RING.  
 
Shortly after the discovery of parkin as a PD-linked gene, three independent 
groups demonstrated parkin’s function as an E3 ligase. Notably, parkin-
mediated ubiquitination is linked to protein degradation and that disease-
associated parkin mutations compromise its role as an E3 enzyme (Imai et al., 
2000; Shimura et al., 2000; Zhang et al., 2000). A logical and popular 
hypothesis that ensued is that loss of parkin function could lead to a toxic 
accumulation of one or several of its substrates, thereby leading to 
neurodegeneration. This had fuelled intense effort by many laboratories 
around the world to identify the culprit substrate(s) involved. To date, no less 
than 25 substrates (or putative substrates) of parkin has been reported since the 
identification of CDCrel1 as the first putative substrate for the ubiquitin ligase 
(Zhang et al., 2000) (Table 3). However, none of the parkin substrates 





raises the question on why these neurons in familial parkinsonism cases linked 
to parkin mutations are selectively vulnerable to deficient parkin function.  
 
Importantly, not all the parkin substrates upon ubiquitination are targeted to 
the proteasome for degradation. For example, several labs including ours have 
demonstrated that parkin is a unique multifunctional enzyme that besides 
mediating K48-linked ubiquitination is also capable of mediating alternative 
ubiquitin topologies such as monoubiquitination and K63-linked 
polyubiquitination – both of which as mentioned earlier are uncoupled from 
the proteasome (Doss-Pepe et al., 2005; Hampe et al., 2006; Lim et al., 2005; 
Matsuda et al., 2006). Specifically, our lab showed that parkin-mediated 
polyubiquitination of synphilin-1 (an interactor of α-synuclein) normally 
occurs via K63-linked chains, which does not appear to affect its steady-state 
turnover. Instead, parkin-mediated K63 polyubiquitination of synphilin-1 
promotes its aggregation into aggresome-like inclusion bodies (Lim et al., 
2005). Similarly, Olzmann et al. demonstrated that parkin-mediated K63 
polyubiquitination of misfolded DJ-1 couples the protein to the dynein motor 
complex via the histone deacetylase 6 (HDAC6) adaptor, thereby promoting 
its sequestration into aggresomes (Olzmann et al., 2007), although they did not 
demonstrate directly that parkin may facilitate aggresome clearance as such. 
Thus, lack of parkin function may retard aggresome formation, which is 








Table 3: Putative parkin substrates 
Substrates Cellular Process Ub Type Reference 
CDCrel-1  Exocytosis - (Zhang et al., 2000) 
CDCrel-2a Exocytosis - (Choi et al., 2003) 
Synaptotagmin  Exocytosis - (Huynh et al., 2003) 
Eps15 Endocytosis  Mono (Fallon et al., 2006) 
Ataxin-2 Endocytosis - (Huynh et al., 2007) 





(Corti et al., 2003; 
Hampe et al., 2006; Ko et 
al., 2005) 
PARIS  Transcription K48 Poly (Shin et al., 2011) 
FBP1 Transcription  - (Ko et al., 2006) 
DJ-1 L166P Transcription  
 
K63  Poly (da Costa, 2007; 
Olzmann et al., 2007) 
Estrogen-related 
receptors 
Transcription  - (Ren et al., 2011) 
Hsp70 Protein QC Mono (Darren J. Moore, 2008) 
α/β tubulin Cytoskeleton - (Ren et al., 2003) 
LIM kinase Cytoskeleton 
dynamics 
- (Lim et al., 2007) 
PICK1 Synaptic scaffolding Mono (Joch et al., 2007) 
IKKγ NF-κB signaling  K63 Poly (Henn et al., 2007) 
Traf2 NF-κB signaling K63 Poly (Henn et al., 2007) 
Phospholipase 
Cγ1 
PKC signaling - (Dehvari et al., 2009) 
Pael-R Probable G-protein 
coupled receptor 
- (Imai et al., 2001) 
Dopamine 
transporter 
Dopamine uptake - (Jiang et al., 2004) 
Cyclin E   Cell cycle regulation - (Staropoli et al., 2003) 
PDCD2-1 Apoptosis - (Fukae et al., 2009) 
Bcl-2 Apoptosis Mono (Chen et al., 2010) 
Bax Apoptosis - (Johnson et al., 2012) 
FAF1 Apoptosis K48 Poly (Sul et al., 2013) 
ARTS Apoptosis - (Kemeny et al., 2012) 
VDAC1 Mitochondria Anion 
channel 
K27 Poly  
Mono 
(Geisler et al., 2010) 
(Narendra et al., 2010a) 
RHOT/Miro Mitochondria transport - (Wang et al., 2011b) 
Mitofusin 1/2  Mitochondria fusion - (Gegg et al., 2010; Poole 
et al., 2010; Ziviani et al., 
2010) 
Drp1 Mitochondria fission K48 Poly (Wang et al., 2011a) 
Ataxin-3 
polyQ79 
Deubiquitnation - (Tsai et al., 2003) 
Fbw7β Ubiquitination  K48 Poly (Ekholm-Reed et al., 
2013) 
DMT1 Iron uptake  - (Roth et al., 2010) 
Hexokinase  Glycolysis  (Okatsu et al., 2012a) 
Synphilin-1 Unknown 
 
K63 Poly (Chung et al., 2001; Lim 
et al., 2005) 
-, denotes unknown. A list of at least 100 postulated parkin substrates in the presence 
of mitochondria depolarization can be found in Sarraf et. al. paper in 2013 (Sarraf et 





1.6.3 Parkin as a key neuroprotectant 
Given the ability of parkin to mediate K63-linked ubiquitination and its role in 
aggresome formation, it is attractive to speculate that parkin-mediated K63-
linked ubiquitination may help protect cells against stress. Indeed, parkin can 
afford considerable protection against a remarkably wide spectrum of cellular 
insults (Feany and Pallanck, 2003; Moore, 2006), including those that promote 
proteasome dysfunction (Petrucelli et al., 2002; Tsai et al., 2003; Wang et al., 
2005). For example, parkin is capable of protecting neurons against toxicity 
mediated by α-synuclein or mutant LRRK2, as well as those generated by 
dopamine quinones, neurotoxins or metallic ions. Moreover, parkin is also 
apparently capable of mitigating cytotoxicity induced by β-amyloid or by 
expanded polyglutamine-containing proteins through facilitating their 
elimination from the cell (either directly via the proteasome or indirectly via 
the aggresome-autophagy pathway) (Burns et al., 2009; Khandelwal et al., 
2011; Tsai et al., 2003). While the removal of aberrant proteins from cells 
undergoing various forms of stress may be a common denominator underlying 
the broad neuroprotective capacity of parkin, recent studies also implicated a 
more direct role for parkin in neuroprotective signalling. Apparently, parkin-
mediated ubiquitination is important for the activation of NF-κB pathway, a 
major cellular pro-survival pathway (Henn et al., 2007). Notably, Henn and 
colleagues demonstrated in cells treated with kainate (an excitotoxin) or 
rotenone (a mitochondrial complex I inhibitor) that parkin-mediated protection 
against cell death is dependent on NF-κB activity (Henn et al., 2007). 





by parkin is associated with its K63 polyubiquitination activity (Henn et al., 
2007).  
 
More recently, parkin has also emerged as a key player in mitochondrial 
homeostasis. Given the high energy demands of neurons, it is apparent that the 
bioenergetic status of mitochondria in these post-mitotic cells needs to be kept 
optimal at all times and that their dysfunction would precipitate 
neurodegeneration. Notably, mitochondrial poisoning recapitulates PD 
features in humans and represents a popular strategy to model the disease in 
animals (Langston et al., 1983; William Langston et al., 1984). Again, the 
ability of parkin to mediate K63-linked ubiquitination appears to be critical for 
this novel function. As mitochondrial homeostasis and the involvement of 
K63-linked ubiquitination in the process is an important topic on its own, I 
have discussed it separately in the next section. 
 
1.7 K63-linked ubiquitination and mitochondrial homeostasis  
In addition to its participation in the autophagic clearance of aggresomes, 
emerging evidence also suggests a role for K63-linked ubiquitination in 
mitochondrial quality control (QC). The sections below provide a primer on 
mitochondrial homeostasis and how it may be regulated by K63-linked 
ubiquitination.   
 
1.7.1 Mitochondrial dynamics 
Mitochondria are the main powerhouses of the cell, producing adenosine 
triphosphate (ATP) needed for all cellular processes. Besides this, the 





of apoptosis. Thus, a highly regulated QC mechanism needs to be in place to 
maintain a stable and functional pool of bio-energetically competent 
mitochondria that is paramount for cell survival.   
 
Unlike the solitary structures depicted in textbooks, mitochondria are dynamic 
and mobile organelles that undergo frequent fusion, fission and degradation 
processes (Fig. 1.6A). These processes allow mitochondria to adapt rapidly to 
any subtle changes in its surroundings particularly in times of cellular stresses.  
 
Mitochondrial fusion is dependent on a group of guanosine triphosphatases 
(GTPase) belonging to the dynamin family, i.e. mitofusin 1 (Mfn1), mitofusin 
2 (Mfn2) and Optic atrophy protein 1 (Opa1) (Fig. 1.6B). Mfn1 and Mfn2 
reside on the outer mitochondrial membrane whereas Opa1 is located on the 
inner mitochondrial membrane. During mitochondrial fusion, Mfn1 or Mfn2 
present on the outer membrane of two neighboring mitochondria mediates the 
formation of a dimeric, antiparallel coiled-coil structure which help tethers the 
two outer mitochondrial membrane together (Koshiba et al., 2004; Santel and 
Fuller, 2001). This step is followed by the fusion of the inner membrane which 
is mediated by Opa1 through an unknown mechanism (Cipolat et al., 2004). 
Although Opa1-mediated fusion of the inner membrane is dependent on Mfn1 
(Cipolat et al., 2004), the reverse is unnecessary as outer membrane fusion is 






Figure 1.6: Mitochondrial homeostasis. (A) Schematic diagram showing the dynamic 
nature of mitochondria. To maintain a healthy, functional pool of mitochondria, 
mitochondria undergo numerous fusion and fission processes. Damaged mitochondria 
that are beyond repair are cleared by mitophagy, a lysosome-mediated process. (B) 
An illustration of the fusion and fission process. The colors denote the degree of 
damage present in the mitochondria with white indicating healthy mitochondria; pink, 
mildly stressed mitochondria and red, highly stressed mitochondria. Left, 
Mitofusin1/2 and Opa1 mediates the fusion of a mildly stressed mitochondrion with a 
healthy mitochondrion. This enables the exchange of contents and complementation. 
Right, A highly stressed mitochondrion undergoes Drp-1 mediated fission to 
segregate damaged components into a daughter mitochondrion which is cleared by 






Mitochondrial fusion occurs during starvation, oxidative stress and impaired 
protein synthesis (Youle and van der Bliek, 2012). In these instances, fusion of 
mitochondria helps to rescue slightly damaged/stressed mitochondria as they 
are able to obtain functional proteins, lipids and metabolic products from 
healthy, active mitochondria. This process is known as complementation. 
Similarly, mutant mDNA (mitochondrial DNA) in one organelle may be 
rescued by another containing wild-type mDNA through complementation 
(Ono et al., 2001). However, there is a limit to the amount of protection 
provided by such fusion events. To guard itself against stress-induced 
problems, the mitochondria (perhaps unsurprisingly) also possess protein QC 
mechanism that is similar to those present in the cytosol. For example, 
mitochondria contain chaperones to aid in the folding of proteins encoded by 
the mDNA and proteases to degrade misfolded or damaged proteins (Baker et 
al., 2011). . 
 
Like fusion, the fission process is also mediated by a GTPase known as the 
dynamin-related protein 1 (Drp1) (Fig. 1.6B). Drp1 is a predominantly 
cytosolic protein that is recruited to the severely stressed mitochondria by the 
mitochondrial fission factor. On the mitochondria, it forms a multimeric ring-
like structure which wraps around the mitochondria and severs it into two 
(Otera et al., 2010; Smirnova et al., 2001).  
 
The process of fission allows for the segregation of damaged mitochondria 
components away from the functional components thus resulting in a healthy 





mitochondrion is then targeted for degradation by mitophagy. This enables the 
cell to isolate damaged mitochondria for degradation while maintaining a 
functional pool of mitochondria (Youle and van der Bliek, 2012). The timely 
removal of damaged mitochondria is obviously important for cell survival as 
their build up will otherwise generate significant problems for cellular 
functions including the production of reactive oxygen species.  
 
1.7.2 Parkin/PINK1 pathway and mitochondrial QC 
Until recently, not much is known about the mechanism underlying 
mitophagy. However, a landmark paper in 2008 showed that parkin together 
with another PD-linked gene known as PINK1, are intimately involved as key 
regulators of the mitophagy process (Narendra et al., 2008) . Like parkin, 
mutations in PINK1 (PTEN-induced kinase 1) are also associated with 
recessive parkinsonism. Whereas parkin is a member of the UPS (i.e. an E3), 
PINK1 is a mitochondrial-localized serine/threonine kinase. Despite their 
apparently different functions, recent studies have demonstrated their inter-
dependent role in regulating mitochondrial QC.  
 
One of the first clues suggesting that Parkin/PINK1 functions are related and 
that both are involved in maintaining the integrity of mitochondria came from 
studies in Drosophila models. In their original report in 2003, Greene et al. 
showed that parkin null Drosophila exhibit reduced lifespan, motor defects 
and male sterility (Greene et al., 2003). Interestingly, the motor defects were 
due to flight muscle degeneration accompanied with swollen mitochondria 





defects precede muscle degeneration, suggesting that mitochondria 
dysfunction leads to the apoptosis of muscle cells. Using a more sensitive 
approach to analyze the Drosophila mutant brains, the same group 
subsequently reported the selective loss of a subset of dopaminergic neurons 
in parkin null flies (Whitworth et al., 2005). A year later, two other groups 
reported the interesting observation that Drosophila PINK1 null mutants also 
display flight muscle degeneration, mitochondria abnormalities and 
dopaminergic neurodegeneration, features which strikingly phenocopy parkin 
null flies (Clark et al., 2006; Park et al., 2006). Importantly, overexpression of 
parkin in PINK1 null Drosophila rescues its phenotype although the reverse 
does not occur, i.e. PINK1 overexpression in parkin null Drosophila was 
unable to rescue parkin null Drosophila phenotype, suggesting that parkin acts 
downstream of PINK1 (Clark et al., 2006; Park et al., 2006).  
 
As a follow up to the above findings, several groups have shown that the 
enhancement of the mitochondrial fission machinery by the overexpression of 
Drp1 (pro-fission) or heterozygous loss-of-function mutation of Opa1 or Mfn 
(pro-fusion) in PINK1 or parkin mutant flies could ameliorate their 
mitochondrial-related phenotypes, suggesting that PINK1 and parkin normally 
promotes mitochondrial fission (Deng et al., 2008; Poole et al., 2008; Yang et 
al., 2008).  However, other groups working with mammalian cells have 
demonstrated that the opposite is true, i.e. parkin and PINK1 promotes 
mitochondrial fusion (Lutz et al., 2009). This discrepancy could be due to the 
differences in mammalian and arthropod cell or a possible compensatory 





Drosophila that is absent in the siRNA knockdown of parkin and PINK1 in 
cultured mammalian cells.      
 
At present, much interest in this topic has been directed towards understanding 
the mechanism of parkin/PINK1 pathway in mitophagy, following the seminal 
discovery by Richard Youle group at NIH that parkin and PINK1 are key 
regulators of this mitochondrial QC mechanism. Using carbonyl cyanide m-
chlorophenyl hydrazone (CCCP), a mitochondria uncoupler which depolarizes 
and damages mitochondria, the Youle group demonstrated that parkin was 
recruited to depolarized mitochondria to mediate their clearance through 
mitophagy (Narendra et al., 2008). Since then, several groups have contributed 
their findings on how the process work, which leads to the formulation of a 






Figure 1.7: Parkin and PINK1- mediated mitophagy. (A) Illustration of PINK1 
processing in healthy mitochondria. TOP: Schematic diagram showing the domains 
present in PINK1. MTS, Mitochondria targeting sequence; TM, Transmembrane. 
Bottom: PINK1 is targeted to the mitochondria with its N-terminal MTS domain 
inserted into the outer membrane (OM) and its kinase domain facing the cytosol. 
PINK1 is imported into the inner membrane (IM) through TOM and TIM and is 
sequentially cleaved by MPP and PARL into a 53kDa PINK1 (PINK1-53). PINK1-53 
is then rapidly degraded. (B) Diagram depicting the process of Parkin/PINK1-induced 
mitophagy. In depolarized mitochondria, PINK1 import into the IM is impeded. Thus 
PINK1 is stabilized on the OM (Step I). PINK1 autophosphorylates itself and recruits 
parkin to the OM (Step II). This activates parkin which then ubiquitinates OM 
proteins via K48- or K63- linked ubiquitin chains (Step III). K48-polyubiquitinated 
proteins are degraded by the proteasome while K63-linked ubiquitination recruits the 







1.7.3 Parkin/PINK1 model of mitophagy 
Broadly speaking (and somewhat arbitrarily), the parkin/PINK1-regulated 
mitophagy process may be divided into 4 inter-related steps (Fig. 1.7B): 
I. PINK1 stabilization on the mitochondrial outer membrane 
II. Recruitment of parkin by PINK1 on the mitochondrial outer membrane 
III. Ubiquitination of mitochondrial proteins by parkin 
IV. Recruitment of autophagy apparatus for mitophagy  
 
STEP1: PINK1 stabilization on the mitochondrial outer membrane - A key 
initial event that occurs upon mitochondrial depolarization is the selective 
accumulation of PINK1 on the outer membrane of the damaged organelle. 
This event does not occur in healthy mitochondria as PINK1 is normally 
processed and degraded.  
 
PINK1, a serine/threonine kinase of 64kDa contains a N-terminal 
mitochondria targeting sequence (MTS) and a C-terminal kinase domain. By 
virtue of the MTS, it is targeted to the mitochondria and oriented such that its 
MTS region inserts into the outer mitochondrial membrane and its kinase 
domain facing the cytosol (Zhou et al., 2008). Under normal mitochondrial 
membrane potential, PINK1 is rapidly imported into the inner mitochondrial 
membrane via the translocase of the outer (TOM) and inner membrane (TIM) 
where it is sequentially cleaved by mitochondria processing peptidase (MPP) 
and presenilins-associated rhomboid-like protein (PARL) to a 53kDa PINK1 
(PINK1-53) species (Greene et al., 2012; Jin et al., 2010). This truncated 





degraded by the proteasome (Fedorowicz et al., 2013; Yamano and Youle, 
2013), which is rather intriguing (Fig. 1.7A). Although the above proteolytic 
events would ensure that PINK1 is kept at low levels under normal conditions 
(and as such to prevent mitophagy from occurring), it is difficult to understand 
why the cell would commit energy to led PINK1 through such an intricate 
processing (i.e. to synthesize, import, cleave it twice, and degrade the protein) 
just to restrict its expression (Note: We have now provided some clarifications 
on this, the results of which are presented in Chapter 4 of this thesis).  
 
STEP II: Recruitment of parkin by PINK1 on the mitochondrial outer 
membrane - Notwithstanding the unresolved rationale surrounding PINK1 
processing, under conditions of acute mitochondrial depolarization (typically 
achieved experimentally by the treatment of cells with mitochondrial 
uncouplers such as CCCP or valinomycin), the importation of PINK1 (a 
membrane potential (ΔΨm)-dependent process) is inhibited due to the 
dissipation of ΔΨm, which allows full length PINK1 to accumulate on the 
outer mitochondrial membrane (Geisler et al., 2010; Matsuda et al., 2010; 
Narendra et al., 2010b; Vives-Bauza et al., 2010). Upon its accumulation, 
PINK1 undergoes autophosphorylation at S228 and S402 (Okatsu et al., 
2012b). Phosphorylated PINK1 then recruits parkin to the depolarized 
mitochondria and activates its ubiquitin ligase activity most likely by 
phosphorylating parkin at S65 (and possibly other sites) (Kondapalli et al., 
2012; Matsuda et al., 2010; Okatsu et al., 2012b). Interestingly, when PINK1 
is experimentally made to localize to peroxisomes or lysosomes, it can also 





these organelles. In contrast, targeting parkin alone to mitochondria, 
peroxisomes or lysosomes in the absence of PINK1 fails to stimulate its 
activity (Lazarou et al., 2012). Thus, membrane-localized PINK1 seems to be 
necessary for parkin recruitment and activation. 
 
STEP III: Ubiquitination of mitochondrial proteins by parkin - Once recruited 
and activated, parkin then mediates the ubiquitination and degradation of 
various outer mitochondrial membrane proteins by the proteasome (Chan et 
al., 2011; Yoshii et al., 2011). One such substrate is mitofusin1/2 (Mfn1/2). 
Upon its ubiquitination, Mfn1/2 is extracted out of the outer mitochondrial 
membrane by an AAA-ATPase known as p97 and degraded by proteasome 
(Poole et al., 2010; Tanaka et al., 2010; Ziviani et al., 2010). This is thought to 
prevent the fusion of depolarized mitochondria with healthy mitochondria, 
thus preventing depolarized mitochondria from mixing and damaging the 
healthy pool of mitochondria. To better define the repertoire of mitochondrial 
substrates that parkin acts on, a recent study conducted by Sarraf and 
colleagues utilized quantitative diGLY proteomics to elucidate the 
ubiquitination site-specificity and topology of parkin-dependent target 
modification in response to mitochondrial depolarization (Sarraf et al., 2013). 
By means of this unbiased approach, they identified hundreds of 
ubiquitination sites that are dynamically regulated and evolutionarily 
conserved in a large number of proteins, with strong enrichment of outer 
mitochondrial membrane proteins. Further, they found via complementary 
interaction proteomics that parkin associates with these targets, as well as with 





associated C431 mutation of parkin disrupt these associations. Whether p97-
mediated extraction is needed here for parkin to ubiquitinate the various outer 
mitochondrial membrane proteins is unclear, although it may seem 
cumbersome for the cell to do so given that a large number of mitochondrial 
proteins would have to be extracted. According to recent studies, parkin may 
instead activate the UPS upon translocation to the mitochondria to facilitate 
the widespread degradation of mitochondrial proteins. However, whether 
proteasome degradation of outer mitochondrial membrane proteins is required 
for the next step in which mitochondria are cleared by autophagy is currently 
debatable. Two independent groups showed that the inhibition of the 
proteasome by MG132 inhibits mitophagy, suggesting that proteasome 
degradation of outer mitochondria proteins is required for mitophagy (Chan et 
al., 2011; Tanaka et al., 2010). However, using electron microscopy, another 
group found that mitochondria degradation occurs in the autolysosome of 
lactacystin- (proteasome inhibitor) treated cells, suggesting that mitophagy is 
independent of the global degradation of outer mitochondrial membrane 
proteins (Yoshii et al., 2011). Moreover, it is also clear now that some targets 
of parkin are enriched (rather than reduced) in response to mitochondrial 
depolarization (Chan et al., 2011; Sarraf et al., 2013), presumably as a result of 
parkin-mediated K63-linked ubiquitination. This particular modification (as 
discussed earlier in the context of aggresome clearance) is thought to help 







STEP IV: Recruitment of autophagy apparatus for mitophagy - 
Notwithstanding the controversy surrounding the role of proteasome 
degradation in the mitophagy process, the induction of mitophagy requires 
parkin-mediated K63-polyubiquitination, although the substrate involved 
remains unclear (Geisler et al., 2010; Lee et al., 2010b; Narendra et al., 2010a; 
Okatsu et al., 2010). Mitochondria substrates that are modified by K63 
polyubiquitin can presumably help in the recruitment of autophagy receptors 
such as HDAC6 and p62 to the damaged organelle (Lee et al., 2010b; 
Narendra et al., 2010a). The whole process thus resembles the formation and 
autophagic clearance of aggresomes. As a matter of fact, prior to the final exit 
of damaged mitochondria from the cell, the organelle first condenses around 
the peri-nucleus region to form aggresome-like structures or “mito-
aggresomes” (Lee et al., 2010b). It would therefore appear that impaired 
mitochondria and protein aggregates are processed by common ubiquitin-
selective autophagic machinery involving the non-classic K63-linked 
ubiquitination.  
 
In essence, mitophagy-associated ubiquitination of proteins appears to be a 
selective process that discriminates degradation-associated targets from those 
that need to evade the destruction. Being a multifunctional ubiquitin ligase 
capable of mediating ubiquitin chains of different topologies, parkin is 







It is conceivable that the timely clearance of damaged mitochondria would 
also potentially prevent the release of pro-apoptotic proteins from the 
organelle. Supporting this, Sun et al. demonstrated that whereas stable 
expression of K48R ubiquitin mutant (which prevents K48-linked 
ubiquitination) in dopaminergic cells significantly attenuates mitochondrial 
apoptosis triggered by pharmacological inhibitors of the proteasome, the 
expression of K63R mutant augments the apoptotic event (Sun et al., 2009). 
These findings suggest that the assembly of K63-linked chains is 
neuroprotective against proteasomal stress-induced mitochondrial dysfunction, 
although it is unclear whether the protection is direct (i.e. K63-linked 
ubiquitination acting on the organelle) or indirect (i.e. through other K63 
polyubiquitin-directed events such as promoting pro-survival NF-B signaling 
and/or sequestration of neurotoxic misfolded proteins).  
 
1.8 Project Aims and Rationales   
The primary goal of my Ph.D. study is to examine the function of K63-linked 
ubiquitination in protein and mitochondrial homeostasis, with the view that the 
knowledge gained could help in the understanding of how this unique 
ubiquitin modification may be involved in diseases such as PD. 
 
Specifically, my project aims to resolve the following gaps in our knowledge 
on K63-linked ubiquitination in protein and mitochondrial homeostasis.   
 
 Pertaining to protein homeostasis, the first part of my project focus on 





involved in cellular response towards proteasomal stress. Although the 
mechanism underlying the preservation of proteasome function by parkin 
is hitherto unclear, it is attractive to speculate that parkin-mediated K63-
linked ubiquitination (which is usually uncoupled from the proteasome) 
may serve to mitigate proteasomal stress by diverting the substrate load 
away from the machinery, especially given our lab’s previous finding that 
K63-linked ubiquitination promotes the formation and autophagic 
clearance of aggresomes. We therefore hypothesize that under conditions 
of proteasomal stress, parkin-mediated K63-linked ubiquitination will be 
enhanced to promote aggresome formation. We further hypothesize that 
the upregulation of K63-linked ubiquitination serves to help the cells 
better cope with proteolytic stress and thereby increasing their 
survivability. My results presented on Chapter 3 support these hypotheses 
and also elucidated the mechanism by which parkin-mediated K63-linked 
ubiquitination is enhanced under conditions of proteasome impairments.  
 
 With regards to the role of K63-linked ubiquitination in mitochondrial 
homeostasis, we are particularly intrigued by the conundrum surrounding 
PINK1 processing, i.e. that cells would commit so much effort to 
synthesize the protein, import it into the mitochondria, and cleave it not 
once but twice only to finally degrade it. We thought that it would make 
more sense for cleaved PINK1 to sub-serve a cellular role, although this 
is speculative and would require the stabilization of PINK1 under some 
unknown conditions. The second part of my project is therefore focused 





unknowns, this was inherently a risky proposition but we hypothesize that 
given the ability of K63-linked ubiquitination to divert substrates away 
from the proteasome, this ubiquitin modification could possibly stabilize 
the cleaved form of PINK1. In essence, this is indeed what I have 
observed and described in Chapter 4 of this thesis. Importantly, I also 
found the ubiquitin ligase involved, which turned out to be TRAF6 rather 
than parkin. The involvement of TRAF6 in NF-κB signaling has led me 
to investigate the potential role of this pathway in PINK1 processing. In 
summary, I found TRAF6-NF-κB pathway to be a major regulator 
governing the stability of cleaved PINK1, which is dependent on K63-
linked ubiquitination. I further found that cleaved PINK1 promotes the 
clearance of normal mitochondria, which is rather curious. Although the 
exact purpose of this is unclear, I propose that this “non-selective 
mitophagy” represents an attempt by the cell to reduce its ROS level in 
times of oxidative stress.   
 
To clarify, the above projects address the role of K63-linked ubiquitination in 
two different scenarios. The two results chapters presented in this thesis are 
therefore not directly linked, nor was it the intention to do so. However, 
emerging evidence suggests that the proteasome and mitochondrial pathways 
are often interwoven and my results may indirectly help in the understanding 













The FLAG-tagged parkin, myc-tagged CHIP, UbcH7 and UbcH8 plasmid 
constructs were a kind gift from Professor R. Takahashi (Kyoto University, 
Japan), while untagged parkin, GFP-tagged Dorfin and HA-HHARI, HA-Cbl 
were provided by Dr. Helen Walden (London Research Institute, UK), 
Professor G. Sobue (Nagoya University, Japan) and Professor G. Guy (IMCB, 
Singapore) respectively. Professor Simone Engelender (Rappaport Institute, 
Israel) kindly provided myc-tagged Siah-1 and -2. HA-tagged synphilin, myc-
tagged synphilin, HA-tagged ubiquitin and its mutants were kindly given by 
Professor Ted Dawson (John Hopkins University, USA). GFP-tagged parkin 
was a kind gift from Professor Yao Tso-Pang (Duke University, USA). 
 
Untag-PINK1 was generated by PCR using PINK1-GFP as a template and 
cloned into pCDNA3 at sites BamHI and EcoRI. DJ-1 was reverse transcribed 
from HEK cDNA and cloned into myc-pcDNA at sites EcoR1 and Not1. Myc-
tagged TRAF6 and myc-tagged Ubc13 were cloned by lab member Dr. Zheng 
Shui. HA-tagged UCHL1 and HA-tagged Senp8 were cloned by lab member 
Jian Xiong and Hui Mei respectively.   
 
Myc-tagged DJ-1 L166P, Flag-tagged parkin mutants and untagged-PINK1 
mutant constructs were generated from their respective plasmid constructs 
using QuickChange site-directed mutagenesis kit (Agilent Technologies, CA, 
USA).   




The following plasmids were obtained from addgene: GFP-tagged ataxin3 
(#22122, Henry Paulson), GFP- tagged A20 (#22141, Yihong Ye), Flag-
tagged IKKβ (#11103, Anjana Rao), Flag-tagged IKKβ K44M (#11104, 
Anjana Rao), Flag-tagged IKKβ S177E /S181E (#11105, Anjana Rao), HA-
tagged IκBα (#21985, Warner Greene) and HA-tagged IκBα S32A/S36A 
(#24143, Warner Greene). Myc,6-His-tagged Mulan, RNF11 and RNF144B 
were purchased from Abgent, San Diego, USA. EGFP-N3 was purchased 
from Clontech, CA, USA.  
 
2.1.2 Antibodies  
The following antibodies that are specific to tags were used: mouse 
monoclonal and rabbit polyclonal anti-FLAG (Sigma, MO, USA), mouse 
monoclonal anti-c-myc (clone 9E10) (Roche Diagnostics, IN, USA), rabbit 
polyclonal anti-c-myc (Bethyl Laboratories, TX, USA), mouse monoclonal 
anti-HA (Roche Diagnostics), rabbit polyclonal anti-HA (Zymed Laboratories, 
CA, USA), mouse monoclonal anti-GFP (Roche Diagnostics). 
 
The following primary antibodies were used: mouse monoclonal anti-β-actin 
(Sigma), mouse monoclonal anti-parkin (clone PRK8) (Covance, NJ, USA),  
mouse monoclonal anti-K63 (clone HWA4C4) (Enzo Life Science, New 
York, USA), rabbit polyclonal anti-K63 (clone Apu3) (Millipore, CA, USA) 
mouse monoclonal anti-Ubc13 (Invitrogen, CA, USA) , rabbit polyclonal anti-
cleaved caspase3 (Cell signaling, MA, USA), mouse monoclonal anti-PARP 
(zymed), rabbit polyclonal anti-PINK1 (Novus biologicals, CO, USA), rabbit 
polyclonal anti-ubiquitin (Dako, Glostrup, Denmark), mouse monoclonal anti-




ubiquitin (clone FK1) (Enzo Life Science), rabbit polyclonal anti-
phosphorserine and anti-phosphothreonine (Millipore), rabbit polyclonal anti-
tim20 (Santa Cruz, TX, USA), mouse monoclonal anti-tim23 (Santa Cruz), 
rabbit monoclonal anti-p65, anti-phospho p65 and anti-phospho IκBα and 
mouse monoclonal anti-IκBα (Cell signaling).  
 
The following fluorescence- or peroxidase- conjugated antibodies were used: 
rhodamine-conjugated anti-mouse and anti-rabbit (Molecular Probes, OR, 
USA), FITC-conjugated anti-mouse (Molecular Probes), FITC-conjugated 
anti-rabbit (BD Pharmingen, NJ, USA), Alexa Fluor 647 anti-mouse and anti-
rabbit (Molecular Probes), monoclonal anti-c-myc and anti-HA peroxidase 
conjugates (Roche), mouse monoclonal anti-flag conjugated peroxidase 
(Sigma) and anti-mouse and anti-rabbit peroxidase conjugates (GE Healthcare, 
Sweden).     
 
2.1.3 Reagents  
The following chemicals were used: Clasto-lactacystin- β-lactone (Enzo Life 
Science), MG132 (A.G. Scientific, CA, USA), Z-IIe-Glu (OtBu)-Ala-Leu-H 
(aldehyde) (PSI) (Peptides International, Osaka, Japan), bafilomycin A1 (A.G. 
Scientific), puromycin (Clontech), blasticidin (Invitrogen). The following 
chemical were purchased from Sigma: 3-methyladenine (3MA), calyculin A, 
dimethyl sulphoxide (DMSO), tumor necrosis factor α (TNFα), propidium 
iodide (PI), phorbol 12-myristate 13-aqcetate (PMA) and carbonyl cyanide M-
chlorophenyl (CCCP). 
 




Synthetic K48- and K63-linked ubiquitin chains were purchased from Enzo 
Life Science while GIPZ Ubc13 shRNA constructs V2LHS_171792 and 
V2LHS_220048 were purchased from Thermoscientific (CO, USA). Mito- 
Tracker Red CMXROS was purchased from molecular probes.  
 
2.2 Methods  
2.2.1 Cell culture  
Human Embryonic Kidney (HEK) 293 cells and SH-SY5Y cells were 
maintained in Dulbecco’s Modified Eagle’s medium (DMEM) (Invitrogen) 
supplemented with 10% fetal calf serum (Invitrogen) and 100units/ml 
Penicillin-Streptomycin (Invitrogen). This media is termed basic media. GFP-
parkin HeLa stable, a kind gift from Noriyuki Matusuda (Tokyo Metropolitan 
Institute of Medical Science were stably maintained in basic media 
supplemented with 5ug/ml puromycin (Clontech, CA, USA). Wild type- and 
Ubc13-knockout (KO) mouse embryonic fibroblast (MEF), a kind gift from 
Yao T.P. (Duke University) were grown in basic media with the addition of 
2mM glutamine (Invitrogen) and 55uM β-Mercaptoethanol (Merck, NJ, USA). 
This media is known as MEF media. Ubc13- and UbcH7- transduced ubc13 
knock-out MEF cells were stably maintained with 10ug/ml blasticidin 
(Invitrogen) in MEF media. Primary MEFs from wild type and parkin null 
mice (exon7 deletion) (von Coelln et al., 2004) were prepared according to 
published protocol (Garfield, 2010) and cultured in  MEF media. All cells 
were maintained in a 5% CO2 atmosphere at 37°C. 
 




24 h after plating, HEK293 cells and GFP-parkin HeLa cells were transiently 
transfected with the desired expression plasmids using LipofectAMINE PLUS 
reagent (Invitrogen) and X-tremeGENE HP DNA transfection reagent (Roche, 
CA, USA) respectively according to the manufacturer’s instructions. 24h after 
transient transfection, cells were treated with the stated reagents for the stated 
time period.  
 
2.2.2 Western blot 
Cells were harvested and lysed on ice with 1% Triton-X 100 (Bio-rad, CA, 
USA), 10ug/ml aprotinin (Roche) and 1mM PMSF (USB, OH, USA) in 
phosphate buffered saline (PBS) (lysis buffer A) for 15mins. Phosphatase 
inhibitor II and III (Sigma) were added to lysis buffer A for experiments that 
involve PINK1. The lysate was then centrifuged at 135,000g for 15 mins at 
4°C. The supernatant obtained is then referred to as the soluble (S) fraction. 
The pellet was then sonicated in 1% sodium dodecyl sulphate (SDS) 
(Invitrogen) and is referred to as the pellet (P) fraction. Equal amount of 
protein from both the soluble and pellet fraction were resolved by SDS-PAGE 
gels at 150V for 1h and transferred to nitrocellulose membrane (Whatman, 
Dassel, Germany) overnight at 30V. The levels of various proteins were 
visualized by ECL detection reagents (Pierce Biotechnology, IL, USA or 
Amersham, UK) and hyperfilm (Amersham, UK).           
 
 





Cells were harvested and lysed on ice with lysis buffer A for 15 mins. The 
lysate was then centrifuged at 20,000g for 15 mins at 4°C and the supernatant 
was collected. Equal amount of protein were then subjected to 
immunoprecipitation with the indicted antibody overnight at 4°C. Protein G 
PLUS/protein A-agarose (Oncogene Science, NY, USA) was added the next 
day for 2h at 4°C, after which the agarose beads were washed 5 times with 1% 
Triton-X 100/PBS. Proteins bound onto beads were extracted by SDS. 
Immunoprecipitates and cell lysates were then resolved and analysed by 
western blot as shown above.  
 
2.2.4 Mitochondria fractionation  
Cells were harvested and lysed in Isontonic buffer (10mM Tris HCL pH 7.4 
(1
st
 base, Singapore), 0.3M sucrose (Sigma), 0.5mM EDTA, 10ug/ml 
aprotinin, 1mM PMSF and 1% (v/v) phosphastase inhibitor cocktail II and III 
in PBS) by pipetting through a 27.5g needle for about 40 times. The lysate was 
centrifuged at 100g for 5 mins at 4°C. The supernatant was collected and span 
at 8,000g for 20 mins at 4°C. The pellet obtained is then referred to as the 
mitochondria fraction. The supernatant is further centrifuged at 20,000g for 20 
mins at 4°C. This supernatant collected is then referred to the cytosolic 
fraction. The mitochondria fraction was then sonicated in 1% sodium dodecyl 
sulphate (SDS). Equal amount of protein from both the mitochondria and 
cytosolic fraction were resolved and analysed by western blotting.  
 
 




2.2.5 2-Dimensional gel electrophoresis 
Cells were harvested and lysed on ice with lysis buffer A plus 1% (v/v) 
phosphastase inhibitor cocktail II and III for 15 mins. The lysate was then 
centrifuged at 20,000g for 15 mins at 4°C and the supernatant was collected. 
60ug of proteins was loaded onto the 1
st
 dimensional 7cm pH 3-11 non-linear 
gel (Amersham, UK) to resolve the proteins according to its isoelectric point. 
It was run as follows, (1) 500V 0.5 h step and hold. (2) 1000V 0.5 h step and 
hold, (3) 5000V 1 h 40 min step and hold. After the 1
st
 dimensional run, the 
gel was placed onto a 12% SDS-PAGE gel for the 2
nd
 dimensional run at 
150V for 1 h. This resolves the proteins according to its molecular mass. The 
proteins were then transferred onto a nitrocellulose membrane (Whatman) 
overnight at 30V. The levels of various proteins were visualized by ECL 
detection reagents (Pierce Biotechnology, IL, USA) and hyperfilm 





HEK cells or 6*10
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GFP-parkin HeLa cells were plated on coverslips 
coated with 10µg/ml poly-L-Lysine (Sigma). 24h after seeding, cells were 
transfected with the respective expression plasmid. 24h after transient 
transfection, cells were treated with the respective reagents for the stated time 
period after which cells were fixed with 2.5% paraformaldehyde (Sigma) 
overnight at 4°C. Cells were then washed 6 times with cold PBS and 
permeabilized with 0.1% Triton X-100/PBS for 2 minutes. Primary antibody 
was added and incubated overnight at 4°C. The cells were than washed 3 times 
with PBS and incubated with secondary antibody for 2h at room temperature 




(RT) in the dark. Cells were then washed 6 times with PBS and mounted with 
vectashield mounting medium with DAPI (Vector Laboratories CA, USA). 
Fluorescent images were acquired with an Olympus confocal microscope.    
 
2.2.7 Inclusion formation and autophagic removal 
The autophagic clearance of inclusions formed under proteasome inhibition 
was examined using a method described by Fortun et al. (Fortun et al., 2003). 
SH-SY5Y cells were transfected with HA-synphilin with either FLAG-tagged 
parkin, myc-tagged Siah-1, myc-tagged Ubc13 or UbcH7 as indicated. 48 h 
after transfection, the cells were treated with 5 µM lactacystin to facilitate the 
formation of synphilin inclusions. After 16 h treatment, the treated cells were 
washed out and allowed to recover in normal media for 24 h. Alongside, 
similarly treated cells were incubated with starvation media (1% serum) to 
stimulate autophagy. Cells were then processed for immunocytochemistry and 
imaged in a blinded manner. At least 50 cells were analysed and the 
percentage of inclusion-positive cells were recorded. Three independent 
experiments were conducted and a bar graph demonstrating the fold difference 
in the average percentage of inclusion-positive cells was drawn. Student t-test 
was performed as a statistical analysis.    
 
2.2.8 Flow cytometry 
6*10
5 
Wild-type or Ubc13-knockout mouse embryonic fibroblast (MEF) cells 
were seeded into a T25 flask. 24h after seeding, MEF cells were treated with 
2µM MG132 for 16h. Floating cells in the media were collected while 
attached cells were dislodged by trypsinization. Cells were pelleted by 




centrifugation at 600rpm for 5mins. Cells were then resuspended in cold PBS 
and counted. Each treatment group was divided into 2 groups, each having 
1*10
6 
cells/ml in 5mM EDTA/PBS. 2ug/ml propidium iodide (PI) (Sigma) 
was added into 1 group while PBS was added into other group as a control. A 
total of 10,000 events were acquired on FACSCailbur (BD Biosciences, USA) 
and data were obtained using FlowJo software (Treestar, OR, USA). The fold 
difference between MG132-treated cells and untreated cells was plotted as a 
bar graph. Technical duplicates and experimental triplicates were done.  
    
2.2.9 Proteasome assay 
Cells were lysed according to that stated in western blot. Proteasome assay 
was performed with fresh lysate using the 20S proteasome activity assay kit 
(Chemicon, CA, USA) according the manufacturer instructions. Technical 
duplicates and experimental triplicates were done.  
 
2.2.10 NF-κB luciferase assay 
HEK cells were transfected with 0.5µg of pSEAP2-control vector, pNFκB-
MetLuc2 reporter vector and the stated plasmids. 24h post-transfection, the 
wells were rinsed with media once before the additional of fresh media. 16h 
later, the media was collected. In the case of treatments, the wells were rinsed 
with media before treatment, replaced with fresh media and the media was 
collected at the end of the treatment. Luciferase assay was performed on 10 
times diluted media with Ready-To-Glow
TM
 dual secreted reporter assay kit 
(Clontech) in accordance to the manufacturer instructions. Technical 
triplicates and experimental triplicates were done. Relative luciferase activity 




was calculated by normalizing the luciferase results with the pSEAP values. 
Luminescence (Fold difference) was computed by normalizing the results to 
control.    




CHAPTER 3: PROTEASOME INHIBITION PROMOTES PARKIN-
UBC13 INTERACTION AND LYSINE 63-LINKED UBIQUITINATION 
 
The majority of the results presented in this chapter have been published  
(Lim GG et al., 2012 PLoS ONE 8(9):e73235) 
 
3.1 Overview 
As mentioned in the introductory chapter, protein homeostasis is a highly 
regulated process that involves the coordinated functions of the chaperone, 
ubiquitin-proteasome and autophagy systems. Together, they prevent the toxic 
accumulation of misfolded proteins that would be otherwise detrimental to 
cellular functions. Whereas the chaperone and ubiquitin proteasome systems 
represent the first lines of defense against the buildup of misfolded proteins, 
the autophagy system also plays an important role in the management of 
misfolded proteins particularly in times of proteolytic stress, e.g. as a result of 
proteasome overloading or impairment. How proteins destined for 
proteasomal degradation are diverted away from the machinery when it 
becomes overwhelmed under conditions of proteolytic stress is however not 
well established, although our lab has originally hypothesized that non-
proteolytic ubiquitination may be involved and subsequently demonstrated 
that K63-linked polyubiquitination promotes the formation and autophagic 
clearance of protein inclusions (Tan et al., 2008b). However, the E3(s) 
involved in this working model of our lab remain elusive. An attractive E3 
candidate is parkin, which we and others have demonstrated to be a unique 
RING1-IBR-RING2-containing E3 capable of mediating multiple forms of 
ubiquitin modifications, including K63-linked ubiquitination (Doss-Pepe et al., 




2005; Hampe et al., 2006; Lim et al., 2005; Matsuda et al., 2006). For 
example, parkin can bind to UbcH7 (or H8) to mediate presumably K48-
linked ubiquitin chains (Imai et al., 2001; Shimura et al., 2000; Zhang et al., 
2000) or to Ubc13 to mediate K63-linked ubiquitin chains. Notwithstanding 
this, the determinants that influence the choice of E2 that partner with parkin 
remain unclear. 
 
Given the above, we hypothesized that K63-linked ubiquitination is 
upregulated in the presence of proteasome impairment and that parkin is a key 
E3 ligase involved. We further hypothesize that the upregulation of K63-
linked ubiquitination serves to help the cell better cope with proteolytic stress 



















3.2.1 K63 polyubiquitinated proteins reside in detergent-insoluble 
fractions of cell lysates.   
To examine the above hypotheses, it would be important for us to first 
investigate whether proteasome impairment increases K63-polyubiquitination 
in parkin-expressing cells. To test this, I would need either K63 ubiquitin-
specific antibody (which will offer a more straightforward approach) or a mass 
spectrometry facility that is equipped to differentiate the various types of 
polyubiquitination (which will be more elaborate and require the collaboration 
with an outside expertise). Fortunately, at the start of my project, K63-specific 
antibodies were commercially available from Enzo Life Science and 
Millipore. As these ubiquitin-specific antibodies were very new, I first 
examine their linkage specificity. With the use of in vitro synthesized K48- 
and K63–linked ubiquitin chains (Fig. 1.2 in Chapter 1), I probed the ubiquitin 
chains with both the Enzo and Millipore K63 antibodies and as a control, I 
included FK1 antibody which recognizes all types of polyubiquitin chains. As 
expected, FK1 antibody recognizes both K48- and K63-linked ubiquitin 
chains. Importantly, both K63 antibodies selectively detect for K63-linked 
ubiquitin chains (Fig. 3.1A). To further establish the specificity of the 
antibody, HEK293 cells were transfected with various types of HA-tagged 
ubiquitin mutants. Triton-X-100 soluble (S) and -insoluble (P) fraction were 
then sequentially prepared from these cells. Notably, K63 antibody from Enzo 
recognizes only polyubiquitin chains formed in K63 ubiquitin mutant 
transfected cells, indicating that the K63 antibody is specific. Interestingly, 
exogenously-introduced K63 ubiquitin species (as visualized via anti-UbK63 




staining) exhibit a tendency to reside in the pellet fraction of cell lysate (Fig. 
3.1B), which is consistent with our lab’s previous finding that K63-
ubiquitination promotes the formation of protein aggregates, which are Triton-
X-insoluble (Tan et al., 2008b). In contrast, the K63 antibody from Millipore 
also recognizes K33- and K48-polyubiquitin chains on top of K63-linked 
ubiquitin chains (Fig. 3.1B). Thus the K63 antibody from Enzo was used in all 
subsequent experiments.  
 
Figure 3.1: K63 polyubiquitinated proteins reside in detergent-insoluble 
fractions of cell lysates. (A) Representative anti-FK1 (polyubiquitination) and anti-
K63 (Enzo and Millipore) immunoblots of chemical synthesized K48- or K63- 
polyubiquitin chains as indicated. (B) Representative anti-HA and anti-K63 (Enzo 
and Millipore) immunoblots of cell lysates sequentially prepared with Triton-X-100- 
(S) and SDS (P)- buffer from HEK293 cells transfected with various ubiquitin 
species, as indicated. The blots above were stripped and reprobed with anti-actin as 
loading control.  
 




I next tested the sensitivity of the K63 antibody towards endogenously-
promoted K63 polyubiquitin chain. For this purpose, HEK293 cells were 
transfected with various E2s that are either not associated with K63-
polyubiquitination, i.e. UbcH7, UbcH8 or exclusively mediates K63-linked 
chains, i.e. Ubc13 (with Uev1a). Disappointingly, the K63 antibody failed to 
detect any enhancement in endogenously promoted K63-polyubiquitination in 
these Ubc13 over-expressing cells (Fig. 3.2A). I surmised that this may be 
related to the sensitivity of the antibody, i.e. the level of endogenous K63-
linked chains produced under these conditions may still be too low for the K63 
antibody to detect. To circumvent this problem, I conducted subsequent 
experiments in cells over-expressing HA-tagged wild-type ubiquitin. Notably, 
K63 ubiquitination can now be observed in the pellet fraction of Ubc13/Uev1a 
over-expressing HEK293 cells, indicating that K63 antibody was able to 
detect exogenously-promoted K63-linked ubiquitination (Fig. 3.2B). 
Accordingly, subsequent experiments were performed in cells expressing 
exogenous HA-tagged wild type ubiquitin. 
 
 





Figure 3.2: K63-linked ubiquitination is enhanced in the presence of Ubc13 
expression. (A) Representative anti-K63 immunoblots of S and P fractions of 
HEK293 cells transfected with various myc-tagged E2s, as indicated. Top and bottom 
arrows point to Uev1a and Ubc13 respectively. The blots above were stripped and 
reprobed with anti-actin as loading control. (B) Same as A except that HEK293 cells 
were co-transfected with HA-tagged wild type ubiquitin and various myc-tagged E2s. 
These experiments were repeated twice with similar results. 
 
Thus the specificity of Enzo K63 antibody was verified, albeit its sensitivity 
was less than optimal (i.e. in the absence of proteasome inhibition – see later 
results). Importantly, K63 immunoreactivity was again observed specifically 
in the pellet fraction in which protein aggregates tend to reside.  
 




3.2.2 K63-polyubiquitination is enhanced in parkin-expressing cells in the 
presence of proteasome inhibition 
To test the hypothesis that K63-polyubiquitination may be enhanced in parkin 
over-expressing cells under conditions of proteasome inhibition, I examined 
K63-immunoreactivity in lysates sequentially prepared with Triton-X-100 (S) 
and SDS buffer (P) from HEK293 cells over-expressing parkin in the absence 
or presence of proteasome inhibition. As expected, I observed a significant 
increase in K63-polyubiquitination in the pellet fraction of untransfected cells 
treated with MG132, a widely used pharmacological proteasome inhibitor, 
compared to untreated cells, suggesting that proteasome inhibition increases 
K63-linked ubiquitination specifically in the pellet fraction (Fig. 3.3A). In the 
case of untreated parkin over-expressing cells, a slight but significant increase 
in K63-polyubiquitination was already evident in the pellet fraction relative to 
its untreated, vector-transfected control counterpart (Fig. 3.3A). Significantly, 
the level of K63-linked ubiquitination in the pellet fraction of these parkin 
over-expressing cells dramatically increases in the presence of MG132 (Fig. 
3.3A). To rule out any off target effects of MG132, I examined the levels of 
K63-linked ubiquitination in parkin over-expressing cells treated with 2 other 
proteasome inhibitors, PSI and Lactacystin (LC). LC in particular is widely 
regarded to be a highly specific inhibitor of the proteasome. DMSO was 
included as a vector control. Similar to MG132, PSI or LC treatment 
dramatically enhances K63-polyubiquitination in parkin over-expressing cells 
compared to untreated cells (Untx), in the pellet fraction. This phenomenon 
was not observed in DMSO-treated cells (Fig. 3.3B, top).  





Figure 3.3: K63-polyubiquitination is enhanced in parkin expressing cells in the 
presence of proteasome inhibition. (A) Left, Representative anti-K63 and anti-
FLAG immunoblots of Triton-X-100- (S) and SDS- (P) soluble lysates prepared from 
untreated or MG132-treated HEK293 cells over-expressing HA-tagged ubiquitin 
alone or with FLAG-tagged parkin, as indicated. The blots above were stripped and 
reprobed with anti-actin as loading control. Right, Bar graph demonstrating the fold 
differences in densitometric levels of K63-polyubiquitination (normalized to 
respective actin levels) under various conditions, as indicated. (**P<0.001 when 
compared to untreated, vector-transfected HEK293 cells; 
##
P<0.001 when parkin 
expressing, MG132-treated cells was compared to MG132-treated cells or parkin 
over-expressing cells, Student’s t-test). (B) Top, Representative anti-K63 and anti-
FLAG immunoblots of S and P fractions of HEK293 cells over-expressing HA-Ub 
alone or with FLAG-parkin in the absence or presence of various pharmacological 
compounds, as indicated. Anti-actin was included as loading control. Bottom, Bar 




graph showing the relative chymotrypsin-like proteasome activity of lysates prepared 
from vector or parkin over-expressing cells treated with the respective proteasome 
inhibitors, as indicated. (**P<0.001 when compared to column 1, Student’s t-test) 
Control refers to lysate added with MG132 in vitro. All experiments were repeated at 
least 3 times with similar results.  
 
 
All 3 proteasome inhibitors significantly decrease proteasome activity when 
compared to untreated cells (Fig. 3.3B, bottom), suggesting that parkin-
mediated increase in K63-linked ubiquitination is indeed a response to 
proteasome impairment. 
 
3.2.3 Parkin-mediated enhancement of K63-polyubiquitination in the 
presence of proteasome inhibition is dependent on its catalytic activity 
and is rather specific to the E3 ligase 
Given that parkin is an E3 ligase, I was naturally curious to know whether the 
increase in K63-linked ubiquitination is dependent on its catalytic activity. To 
address this, several parkin RING mutants that are catalytically compromised 
were used. Substitution of wild-type parkin with a truncated parkin mutant (Δ 
RING) that is devoid of the C-terminal RING1-IBR-RING2 catalytic domain 
dramatically reduces the level of K63-linked ubiquitination in the presence of 
MG132 (Fig. 3.4). Similarly, parkin disease-associated RING mutants, T240R, 
T415N and G430D abolishes parkin-mediated enhancement of K63-
polyubiquitination in the presence of MG132 (Fig. 3.4). Conversely, parkin 
M192L mutant whose mutation resides outside of the RING catalytic domain 
maintains its ability to mediate K63-linked ubiquitination (Fig. 3.4). These 
results suggest that parkin-mediated increase in K63-polyubiquitination upon 
proteasome impairment is dependent on parkin’s catalytic activity.  
 





Figure 3.4: Parkin-mediated enhancement of K63-linked ubiquitination in the 
presence of proteasome inhibition is dependent on its catalytic activity. 
Representative anti-K63 immunoblots of S and P fractions prepared from MG132-
treated HEK293 cells expressing FLAG-tagged wild-type parkin or various parkin 
mutants, as indicated. The blots above were stripped and reprobed with anti-actin as 
loading control. All experiments were repeated at least 3 times with similar results.  
 
I next investigated if this phenomenon is specific to parkin as an E3 ligase (i.e. 
compared to other E3 members). I replaced parkin with HHari, Cbl, Siah-1 
and C-terminus of Hsc70 interacting protein (CHIP). HHari is an E3 ligase 
that belongs to the RING-IBR-RING ligase family similar to parkin while Cbl 
and Siah-1 belong to the RING ligase family. These 3 ligases are not known to 
be associated with K63-polyubiquitination. CHIP, a U-box E3 ligase, is 
known to mediate K63-linked ubiquitination (Fig. 3.5A). HHari, Cbl and Siah-
1 did not lead to an increase in K63-linked ubiquitination in the presence of 
proteasome inhibition, whereas CHIP promotes K63-polyubiqutination in the 
pellet fraction when exposed to proteasome inhibition (Fig. 3.5B). Taken 
together, the above results suggest that in the presence of proteasome 
inhibition, parkin promotes K63-linked ubiquitination in the pellet fraction and 
this is dependent on its catalytic domain and that this phenomenon is rather 
specific (although not exclusive) to parkin.  





Figure 3.5: Proteasome inhibition-related enhancements in K63- 
polyubiquitination is rather specific (but not exclusive) to parkin.  (A) Schematic 
diagram displaying the domains present in the various E3 ligases. UBL, ubiquitin-
like; RING, Really interesting new gene; IBR, In-between-ring; TKB, Tyrosine-
kinase binding; UBA, ubiquitin-associated; TPR, tetratricopeptide. (B) 
Representative anti-K63 immunoblots of S and P fraction obtained from MG132-
treated cells expressing FLAG-tagged parkin, HA-tagged HHari or Cbl, myc-tagged 
Siah-1 or CHIP, as indicated. The blots above were stripped and reprobed with anti-
actin as loading control. All experiments were repeated at least 3 times with similar 
results.  
 
3.2.4 Proteasome inhibition promotes the recruitment of Ubc13 by parkin  
As Ubc13 is the only E2 known to date to mediate K63-linked ubiquitination 
and I have shown that parkin-mediated K63-polyubiquitination is promoted 
under proteasome impairment, it is likely possible that proteasome inhibition 
increases parkin and Ubc13 interaction. To investigate this, I conducted co-
immunoprecipitation with lysates prepared from HEK293 cells transfected 
with Ubc13 and Parkin in the absence or presence of proteasome inhibition. 
As expected, the level of parkin pulled-down with Ubc13 is significantly 
enhanced in the presence of MG132 (Fig. 3.6A). Moreover, the levels of 




Ubc13 and importantly parkin in the lysate (INPUT) did not increase with 
proteasome inhibition (Fig. 3.6A), suggesting that the enhanced pulled-down 
observed is likely due to increase parkin and Ubc13 binding affinity. This 
phenomenon was also observed when the cells were treated with 2 other 
proteasome inhibitors, PSI and Lactacystin (LC), but not with DMSO, a 
vehicle control (Fig. 3.6B). This correlates with the increase in K63-linked 
ubiquitination seen earlier (Fig. 3.3B). Parkin reportedly also interacts with 
UbcH7, an E2 that mediates non-K63-linked ubiquitination (Shimura et al., 
2000). Thus, I next examined whether the increase in parkin and Ubc13 
interaction is specific to Ubc13. UbcH6 was included as a negative control as 
parkin and UbcH6 is not known to interact (Shimura et al., 2000) , which was 
observed to be the case (Fig. 3.6C). When Ubc13 was replaced with UbcH7, 
the E2 did not co-immunoprecipitate with parkin either in the absence or 
presence of proteasome inhibition (Fig. 3.6C).  Notwithstanding the reason as 
to why UbcH7 failed to bind to parkin, the result suggests that the increase in 
parkin and Ubc13 interaction is specific to Ubc13.  
 
I next went on to investigate whether other E3 ligases exhibit the same 
phenomenon as parkin. I replaced parkin with HHari or CHIP and subjected 
the transfected cells to proteasome inhibition. Corresponding to results 
obtained in Fig. 3.5B, HHari, which did not mediate an increase in K63-linked 
ubiquitination in the presence of MG132, did not exhibit an increase in 
interaction with Ubc13 under proteasome inhibition (Fig. 3.6D). Conversely, 
CHIP, which increases K63-polyubiquitination upon proteasome inhibition 




(Fig. 3.5B) also display enhanced interaction with Ubc13 under such 
conditions (Fig. 3.6D).  
 
Figure 3.6: Proteasome inhibition promotes the recruitment of Ubc13 by parkin. 
(A)Left, HEK293 cells were transfected with FLAG-tagged parkin alone or with myc-
tagged Ubc13 in the absence or presence of proteasome inhibition. Representative 




anti-FLAG and anti-myc immunoblots of a portion of Triton-X-100 soluble lysates 
subjected to anti-myc immunoprecipitation (IPmyc). The remaining lysates were 
probed with anti-myc and anti-FLAG to indicate the levels of myc-tagged Ubc13 and 
FLAG-tagged parkin respectively (INPUT). Right, Bar graph showing the fold 
differences in densitometric levels of parkin that co-immunoprecipitated with Ubc13 
(normalized to respective Ubc13 pulled-down levels) from untreated or MG132-
treated HEK293 transfected cells ( *p<0.05, Student’s t-test). (B-C) Same as above 
except that (B) MG132 treatment was replaced by DMSO, PSI or Lactacystin (LC) 
treatment, or (C) myc-tagged Ubc13 was substituted with myc-tagged UbcH7 or 
UbcH6. (D) Left, Same as (A) except that FLAG-tagged parkin was replaced by HA-
tagged HHari and anti-FLAG immunoblots were substituted with anti-HA 
immunoblots. * denotes non-specific band. Right, Same as (A) except that 
immunoprecipitation was performed with anti-Ubc13. FLAG-tagged parkin was 
substituted with myc-tagged CHIP and anti-FLAG immunoblot was replaced by anti-
myc immunoblot. These experiments were replicated at least three times. Figure B 
was contributed by Roy sim.       
 
Taken together, the above results suggest that the enhanced interaction 
between parkin and Ubc13 in the presence of proteasome inhibition is rather 
specific and this could account for the increase in parkin-mediated K63-linked 
ubiquitination observed during proteasome impairment.     
 
3.2.5 Proteasome inhibition promotes the interaction between untagged 
parkin and Ubc13 and concomitantly enhances K63-linked 
ubiquitination.  
A recent paper suggests that parkin exists in an auto-inhibited state and that N-
terminal tagging of parkin could relieve its auto-repression (Burchell et al., 
2012). Thus, I examined whether proteasome inhibition can relieve parkin 
repression and promote parkin-Ubc13 interaction which may lead to enhanced 
K63-linked ubiquitination. To address this, I used an untagged form of parkin 
in this investigation. Interestingly, proteasome inhibition enhances untagged-
parkin and myc-tagged Ubc13 interaction (Fig. 3.7A) and this leads to a 
corresponding increase in K63-linked ubiquitination in the pellet fraction of 
untagged-parkin expressing cells in the presence of MG132 (Fig. 3.7B).  





Figure 3.7: Proteasome inhibition promotes the interaction between untagged 
parkin and Ubc13 and concomitantly enhances K63-linked ubiquitination. (A) 
HEK293 cells were transfected with untagged parkin alone or with myc-tagged 
Ubc13 in the absence or presence of proteasome inhibition. Representative anti-
parkin and anti-myc immunoblots of a portion of Triton-X-100 soluble lysates 
subjected to anti-myc immunoprecipitation (IPmyc). The remaining lysates were 
probed with anti-myc and anti-parkin to indicate the levels of myc-tagged Ubc13 and 
untagged parkin respectively (INPUT). (B) Representative anti-HA and anti-K63 
immunoblots of Triton-X-100- (S) and SDS- (P) soluble lysates prepared from 
untreated or MG132- treated HEK293 cells over-expressing HA-tagged ubiquitin 
alone or with untagged parkin, as indicated. The blots above were stripped and 
reprobed with anti-actin as loading control. Experiments were repeated at least twice.  
 
Thus, if untagged parkin is indeed kept at an inactivated state, proteasome 
inhibition can apparently relieve its repression to result in an enhancement of 
its K63 ubiquitination activity. 
 




3.2.6 Endogenous parkin and Ubc13 are required for enhanced K63-
linked ubiquitination in the presence of proteasome inhibition. 
The results above were obtained in a cellular over-expression system, which 
may raise the concern that the observations are a result of an over-expression 
artifact. To address this, I examined the levels of K63-polyubiquitiantion in 
Ubc13-knockdown HEK293 cells and parkin-knockout Mouse Embryonic 
Fibroblast (MEF) in the absence or presence of MG132.  
 
ShRNA-mediated Ubc13-knockdown cells transfected with FLAG-tagged 
parkin exhibit a reduction in the levels of K63-linked ubiquitination in the 
presence of MG132 compared to control cells (Fig. 3.8A). Interestingly, the 
level of over-expressed FLAG-tagged parkin was also reduced in Ubc13-
knockdown cells, suggesting that Ubc13 could play a role in parkin 
stabilization (Fig. 3.8A). Importantly, parkin-knockout (Parkin -/-) MEFs also 
display a reduction in K63-polyubiquitination compared to Wild-type (WT) 
MEF in the presence of MG132 (Fig. 3.8B).  
 





Figure 3.8: Endogenous Parkin and Ubc13 are required for enhanced K63-
linked ubiquitination in the presence of proteasome inhibition. (A) Representative 
anti-K63, anti-Ubc13 and anti-FLAG immunoblots of Triton-X-100- (S) and SDS- 
(P) soluble lysates prepared from MG132-treated, FLAG-parkin and HA-Ub 
transfected HEK293 cells in the absence or presence of Ubc13 shRNA species or 
control shRNA, as indicated. Anti-actin was included as control. (B) Representative 
anti-K63 and anti-parkin immunoblots of Triton-X-100- (S) and SDS- (P) soluble 
lysates prepared from untreated or MG132-treated wild-type (WT) or parkin-
knockout (Parkin -/-) mouse embryonic fibroblast, as indicated. Arrow denotes anti-
parkin band. * denotes non-specific band. The blots above were stripped and 
reprobed with anti-actin as loading control. These experiments were repeated at least 
twice.  
 
Together, these results suggest that parkin-mediated increase in K63-linked 
ubiquitination and the involvement of Ubc13 in the presence of proteasome 
inhibition is unlikely to be an artifact of the over-expression system.          
 
3.2.7 Parkin does not appear to be phosphorylated in the presence of 
MG132.  
I have shown that proteasome inhibition increases parkin and Ubc13 
interaction and concomitantly enhances K63-linked ubiquitination. However, 
the mechanism by which proteasome inhibition increases parkin and Ubc13 
binding affinity is unknown. Interestingly, a recent paper by Sha and 




colleagues showed that PTEN-induced kinase 1 (PINK1)-mediated 
phosphorylation of parkin enhances its interaction with Ubc13 and in turn 
promotes K63-linked ubiquitination (Sha et al., 2010). Thus, I next examined 
whether proteasome inhibition similarly induces parkin phosphorylation. For 
this purpose, parkin was immunoprecipitated from untreated or MG132-
treated HEK cells and its phosphorylation status examined by immunoblotting 
with anti-phosphoserine and anti-phosphothreonine antibodies (which were 
used by Sha et. al). However, parkin phosphorylation was not detected in the 
absence or presence of MG132, or even in the presence of PINK co-
transfection, which was included as a control (Fig. 3.9A). Both phosphoserine 
and phosphothreonine antibodies are able to detect for its respective 
phosphoprotein accumulation in the presence of calyculin A, a potent inhibitor 
of protein phosphatase 1 and 2A, suggesting that the antibodies were working 
fine (Fig. 3.9B). Taken together, this would suggest that parkin is not 
phosphorylated upon proteasome inhibition. However, as both phosphoserine 
and phosphothreonine immunoblotting are well known to be tricky, I also 
analyzed the electrophoretic mobility of parkin prepared from untreated or 
MG132-treated cells by 2-dimensional gel electrophoresis. If parkin is 
phosphorylated in the presence of MG132, it would migrate to the acidic side 
of the gel as seen with lysate prepared from cells transfected with Wild-type 
(WT) parkin and a phospho-mimetic parkin T175D mutant (arrow) (Fig. 
3.9C). However, parkin prepared from untreated and MG132-treated cells 
migrate to a similar region of the gel (Fig. 3.9C), suggesting the parkin is 
indeed not phosphorylated in the presence of proteasome inhibition. Taken 
together, the results above suggest that parkin phosphorylation is unlikely to 




account for the increase in parkin and Ubc13 binding affinity in the presence 
of proteasome inhibition.  
 
 
Figure 3.9: Parkin does not appear to be phosphorylated in the presence of 
MG132. (A) HEK293 cells were transfected with FLAG-tagged parkin alone or with 
untagged-PINK1 in the absence or presence of proteasome inhibition. Anti-
phosphoserine (pSer), anti-phosphothreonine (pThr) and anti-FLAG immunoblots of 
a portion of Triton-X-100 soluble lysate subjected to anti-FLAG immunoprecipitation 
(IPflag). The remaining lysates were probed with anti-PINK1 (INPUT). (B) Anti-
pSer and anti-pThr immunoblots of SDS-soluble lysates prepared from HEK293 cells 
treated with DMSO or Calyculin A, a potent protein phosphatase inhibitor. (C) Anti-
FLAG immunoblots of 2-dimensional gel electrophoresis of Triton-X-100 soluble 
lysates prepared from FLAG-tagged parkin transfected cells in the absence or 
presence of MG132 treatment (Top and middle panels). As a control, wild-type (WT) 
parkin was co-expressed with phospho-mimetic FLAG-tagged parkin mutant T175D. 
A more acidic parkin-positive spot (Arrow) which corresponds to parkin mutant 
T175D was observed alongside the unmodified spot (Bottom panel). Figure B was 
kindly provided by Adeline.      
 
The precise mechanism by which parkin-Ubc13 interaction is enhanced in the 
presence of proteasome inhibition thus awaits future clarification.  
 




3.2.8 Accumulation of synphilin-1 in cells expressing K63 mutant 
ubiquitin.  
Previously, our lab has shown that the ubiquitination of synphilin-1 (a 
substrate of parkin) by parkin and Siah-1 occurs via K63 and K48 respectively 
(Lim et al., 2005). Since my results showed that K63-linked ubiquitination 
resides exclusively in the Triton-X-100 insoluble (P) fraction, one would 
expect that synphilin-1 would then reside in the P fraction if it is ubiquitinated 
by parkin via K63-linked ubiquitination. Indeed, co-transfection of synphilin-1 
with parkin promotes synphilin-1 accumulation in the P fraction (Fig. 3.10A). 
This phenomenon was not observed with 3 other E3 members, Siah-1, Siah-2 
and Dorfin, all of which have been shown to promote K48-ubiquitination on 
synphilin-1 (Ito et al., 2003; Liani et al., 2004; Nagano et al., 2003). Instead, 
these three other E3 ligases result in a significant decrease in synphilin-1 
levels both in the Triton-X-100 soluble and insoluble fraction (Fig. 3.10A), 
suggesting that synphilin-1 is being degraded. As CHIP also mediates K63-
linked ubiquitination, I examined the levels of synphilin-1 in the presence of 
CHIP. CHIP did not result in a change in synphilin-1 levels (Fig. 3.10A), 
suggesting that CHIP is not an E3 ligase for synphilin-1. To further verify that 
parkin-induced synphilin-1 increase in the pellet fraction is due to K63-linked 
ubiquitination, I examined the levels of synphilin-1 in the presence of various 
ubiquitin mutants. Expectedly, co-expression of synphilin-1 with K63 and 
K48R ubiquitin mutant increases synphilin-1 levels in the P fraction, although 
K0 also result in a similar phenomenon (Fig. 3.10B, C). Given the recent 
finding by Winklhofer’s group that parkin is capable of mediating linear 
ubiquitin chain (Müller-Rischart et al., 2013); there is a possibility that parkin 




may promote linear chain ubiquitination in the presence of K0 ubiquitin 
mutant thereby resulting in the stabilization of synphilin-1 in the P fraction. As 
linear and K63 ubiquitin chains are structurally quite similar, I tested to see if 
the K63 antibody might recognize K0-ubiquitinated proteins but found no 
evidence of their cross-reactivity (data not shown). Notwithstanding this, I 
have shown that K63 ubiquitin mutant increases synphilin-1 levels in the 
pellet fraction.  
 
Figure 3.10: Accumulation of synphilin-1 in cells expressing K63 mutant 
ubiquitin. (A) Left, Representative anti-HA, anti-FLAG, anti-myc and anti-GFP 
immunoblots of Triton-X-100- (S) and SDS- (P) soluble lysates prepared from 




HEK293 cells over-expressing HA-tagged synphilin-1 alone or with FLAG-tagged 
parkin, myc-tagged Siah-1 or -2, myc-tagged CHIP or GFP-tagged dorfin, as 
indicated. Anti-actin was included as a loading control. Right, Bar graph 
demonstrating the relative densitometric levels of synphilin-1 in S and P fractions 
(normalized to respective actin levels) under various conditions, as indicated. 
(*P<0.05, **P<0.001, Student’s t-test) (B-C) Representative anti-myc and anti-HA 
immunoblots of Triton-X-100- (S) and SDS- (P) soluble lysates prepared from 
HEK293 cells over-expressing myc-tagged synphilin-1 alone or with HA-tagged 
ubiquitin and its various mutants, as indicated. The blots above were stripped and 




3.2.9 Synphilin-1 and mutant DJ-1 over-expression further promotes 
parkin-Ubc13 interaction.  
Given that synphilin-1 is apparently ubiquitinated by parkin via K63-linked 
ubiquitination (Lim et al., 2005), it is likely that synphilin-1 over-expression in 
the presence of proteasome inhibition might further enhance the recruitment of 
Ubc13 by parkin. Indeed, I observed that parkin and Ubc13 interaction is 
significantly enhanced in the presence of over-expressed synphilin-1. 
Interestingly, this phenomenon is observed in MG132-treated cells but not in 
untreated cells. In fact, over-expression of synphilin-1 in untreated cells seems 
to decrease parkin and Ubc13 binding although this might be due to a decrease 
in FLAG-tagged parkin levels in the lysate to begin with (INPUT) (Fig. 
3.11A). Besides synphilin-1, DJ-1 L166P mutant has been shown to be 
ubiquitination by parkin via K63-linked ubiquitination under conditions of 
proteasome impairment (Olzmann et al., 2007). Thus, I next examined 
whether over-expression of DJ-1 L166P mutant is able to enhance parkin and 
Ubc13 interaction in MG132-treated cells. Similar to synphilin-1, 
overexpression of DJ-1 L166P mutant greatly enhances parkin and Ubc13 
interaction in the presence but not in the absence of MG132 (Fig. 3.11B). 
These suggest that in the presence of proteasome inhibition, parkin 




preferentially recruits Ubc13 to mediate K63-linked ubiquitination on its 
substrates.     
 
Figure 3.11: Synphilin-1 and mutant DJ-1 over-expression further promotes 
parkin-Ubc13 interaction. (A) HEK293 cells were transfected with FLAG-tagged 
parkin alone or with myc-tagged Ubc13 and/or HA-synphilin-1 in the absence or 
presence of proteasome inhibition. Representative anti-FLAG, anti-myc and anti-HA 
immunoblots of a portion of Triton-X-100 soluble lysates subjected to anti-myc 
immunoprecipitation (IPmyc). The remaining lysates were probed with anti-FLAG, 
anti-myc and anti-HA to indicate the levels of FLAG-tagged parkin, myc-tagged 
Ubc13 and HA-tagged synphilin-1 respectively (INPUT). (B) Same as (A) except that 
HA-tagged synphilin-1 was replaced with myc-tagged DJ-1 L166P and the 
immunoprecipitation was performed with anti-Ubc13 antibody. All experiments were 
repeated at least 2 times with similar results. Figure A was kindly contributed by 
Katherine Chew.  
 
 
3.2.10 Parkin facilitates the autophagic clearance of synphilin-1 inclusions 
formed in the presence of proteasome inhibition.  
Recent studies from our lab and others suggest that K63-linked ubiquitination 
may act as a signal that targets proteins to the aggresome-autophagy system 




(Olzmann et al., 2007; Tan et al., 2008b). Thus parkin may facilitate the 
autophagic clearance of synphilin-1 aggregates formed in the presence of 
proteasome inhibition. By means of an inclusion clearance assay described 
previously (Tan et al., 2008b), we found that over-expressed parkin but not 
over-expressed Siah-1 promotes autophagic clearance of synphilin-1 
inclusions formed in the presence of proteasome inhibition (Fig. 3.12A). 
Significantly, we found that synphilin-1 inclusions generated in cells over-
expressing Ubc13 and Uev1a are cleared by autophagy (Fig. 3.12B). However, 
synphilin-1 inclusions formed in UbcH7 over-expressing cells are not 
amenable to autophagic clearance (Fig. 3.12B).  Taken together, the enhanced 
parkin and Ubc13 interaction in the presence of over-expressed synphilin-1 
and proteasome inhibition may serve as a cellular response that promotes the 
autophagic clearance of synphilin-1 inclusions and presumably other parkin 
substrates that are ubiquitinated via K63-linked ubiquitination by the E3.  
 
Figure 3.12: Parkin facilitates the autophagic clearance of synphilin-1 inclusions 
formed in the presence of proteasome inhibition. Bar graph demonstrating the 
relative fold differences in the number of synphilin-1-positive inclusions formed in 
lactacystin-treated SH-SY5Y cells co-expressing (A) parkin or Siah-1, or (B) 
Ubc13/Uev1a or UbcH7, that were allowed to recover in normal (no autophagy 
induction, -) or low serum (autophagy induced, +) medium. (*P<0.05, **P<0.001 
compared to control group, Student’s t-test) This figure was kindly contributed by 
Katherine Chew.  
 
 




3.2.11 K63-polyubiquitination protects cells against proteasome 
inhibition-induced cytotoxicity.  
Given that parkin has been shown to protect against proteasome inhibition-
induced cell death (Petrucelli et al., 2002) and that my results above shows 
that K63-linked ubiquitination increases with proteasome inhibition and 
facilitates the clearance of protein inclusions, I hypothesized that the 
upregulation of K63-polyubiquitination in the presence of proteasome 
impairment may be protective. To address this, I treated Wild-type (WT) and 
Ubc13-knockout (Ubc13 -/-) mouse embryonic fibroblast (MEF) with MG132 
and examine their relative susceptibility to proteasome inhibition-induced cell 
death. Aligning with my hypothesis, I observed that a huge proportion of 
MG132-treated Ubc13-/- MEF are rounded and reflective (indicative of dying 
cells) while most MG132-treated WT MEF are devoid of such features (Fig. 
3.13A). For a quantitative measurement of cell death, I carried out Propidium 
Iodide (PI) staining (which stains for dead cells as the DNA dye is membrane 
impermeant and usually excluded from viable cells) followed by flow 
cytometry. Similar to the morphological observation above, flow cytometry PI 
measurement revealed significantly more dead cells in MG132-treated Ubc13-
/- MEF compared to WT MEF (Fig. 3.13B, left) despite the fact that 
proteasome activity decreased to a similar level in both cell lines (Fig. 3.13B, 
right), suggesting that Ubc13-mediated K63-linked ubiquitination protects 
against proteasome inhibition-induced cell toxicity. Consistent with this, 
western analysis with two cell death markers, i.e. cleaved caspase 3 and poly 
(ADP-ribose) polymerase (PARP), revealed a significant increase in cell death 
in MG132-treated Ubc13-/- MEF compared to MG132-treated WT MEF (Fig. 




3.13C). Notably, a dose-dependent increase in cell death is observed in 
Ubc13-/- cells exposed to MG132 (Fig. 3.13C). These suggest that Ubc13 is 
necessary to protect cells against proteasome inhibition-induced cell death.  
 
Importantly, the level of K63-linked ubiquitination is reduced (although 
curiously not complete absence) in MG132-treated Ubc13-/- MEF when 
compared to WT MEF (Fig. 3.13D). Notably, the level of K63-
polyubiquitination increases in a dose-dependent manner in both cell lines 
(Fig. 3.13D). Thus Ubc13-mediated K63-linked ubiquitination fulfills a 
protective role against proteasome inhibition.  
 
Significantly, reconstitution of Ubc13-/- MEF with over-expressed Ubc13 
greatly reduces cleaved caspase 3 and cleaved PARP levels in the presence of 
proteasome inhibition compared to parental Ubc13-/- MEF. Conversely, over-
expression of UbcH7 into Ubc13-/- MEF appears to aggravate cell death 
induced by MG132 (Fig. 3.13E). Thus, the up-regulation of Ubc13-mediated 
K63-linked ubiquitination in the presence of proteasome impairment appears 





    






Figure 3.13: K63-polyubiquitination protects cells against proteasome 
inhibition-induced cytotoxicity. (A) Representative phase-contrast images showing 
an obvious increase in the population of rounded and reflectile cells in MG132-
treated Ubc13-/- MEF compared to untreated or MG132-treated Wild-type MEF. (B) 
Bar graph showing the relative cell dead (Fold difference between MG132-treated 
cells/ untreated cells) (Left) and proteasome activity (Right) of wild type and Ubc13-




/- MEF in the absence or presence of MG132 treatment (1 or 2µM, as indicated). (C) 
Representative anti-cleaved caspase 3 and anti-PARP immunoblots of Triton-X-100 
soluble and insoluble lysates prepared from untreated or MG132-treated wild type or 
Ubc13-/- MEF. The blots were stripped and reprobed with anti-actin as loading 
control. (D) Same as (C) except that lysates were probed with anti-Ubc13 and anti-
K63 antibody. (E) Same as (C) except that Ubc13-/- MEF transduced with lenti-
Ubc13 or -UbcH7 were used. These experiments were repeated at least three times.  
 
 
3.2.12 NF-κB activity is elevated in MG132-treated cells but is not further 
enhanced in the presence of overexpressed parkin. 
A study by Winklhofer’s group showed that parkin promotes K63-linked 
ubiquitination of IκB kinase γ (IKKγ) and activates the NF-κB pathway (Henn 
et al., 2007), the upregulation of which may serve to protect cells against 
proteolytic stress. Thus, I next examined whether the enhancement of parkin-
mediated K63-linked ubiquitination under proteasome inhibition activates the 
NF-κB pathway. Using NF-κB luciferase assay (Fig. 3.14A), I found that 
proteasome inhibition significantly increases the activity of NF-κB pathway 
(Fig. 3.14B). However, over-expression of parkin in MG132-treated cells did 
not increase the NF-κB activity further, suggesting that parkin-mediated 
increase in K63-linked ubiquitination under proteasome inhibition is probably 
not activating the NF-κB pathway (Fig. 3.14B). However, as the luciferase 
assay requires the co-transfection of 3 different plasmids (NF-κB reporter, 
internal control and FLAG-tagged parkin plasmids), the probability of triple 
transfected cells might be low and this might account for the observed lack of 
increase in NF-κB activity. To test this, I repeated the above experiment and 
alongside it co-transfected TRAF6, an E3 ligase essential for NF-κB 
activation, with the NF-κB reporter and the internal control plasmid. Notably, 
TRAF6 leads to a dramatic increase in NF-κB activity (Fig. 3.14C), indicating 
that this assay works with triple transfection. Interestingly, TRAF6 increases 




the NF-κB activity by 70 folds as compared to a 2 fold increase mediated by 
MG132. This difference might be a result of an over-expression system in the 
case of TRAF6 whereas MG132-mediated increase in NF-κB activity is 
dependent on an endogenous system.  
 
To verify the involvement of the NF-κB pathway further, western blot analysis 
with phospho p65 and IκBα (markers for activated NF-κB signaling) was 
performed. Similar to the luciferase result, TRAF6 over-expression and 
proteasome inhibition increases NF-κB signaling. Significantly, parkin over-
expression did not enhance NF-κB activation above that observed with 
proteasome inhibition.  
 
Taken together, the above results suggest that the increase in K63-linked 
ubiquitination mediated by parkin in the presence of proteasome inhibition is 
probably not acting through the NF-κB pathway but instead serves to promote 
the formation and clearance of protein inclusions and as such help to prevent 
the toxic accumulation of misfolded proteins. 





Figure 3.14: NF-kB activity is elevated in MG132-treated cells but is not further 
enhanced in the presence of overexpressed parkin. (A) Schematic diagram 
displaying the work flow involved in NF-κB luciferase assay. (B) Bar graph showing 
the relative fold difference in luminescence detected in the media of untreated or 
MG132-treated HEK293 cells transfected with vector alone or FLAG-tagged parkin 
(Top), or vector alone or myc-tagged TRAF6 (Bottom), as indicated. The values were 
obtained in the same experiment but presented as 2 different graphs to illustrate the 
fold differences. (C) Anti- phospho p65, anti-p65, anti-phospho IκBα, anti-IκBα 
immunoblots of Triton-X-100 soluble lysates prepared from HEK cells over-
expressing vector, parkin or TRAF6 in the absence or presence of proteasome 
inhibition, as indicated. Experiments were done at least three times except for C) 
which was done once.   
 
 





In essence, the main finding of my study described in this chapter is that 
proteasome inhibition promotes parkin-Ubc13 interaction and concomitantly 
enhances parkin-mediated K63-linked ubiquitination. The study thus identifies 
a mechanism by which parkin could promote K63-linked ubiquitin 
modification in cells undergoing proteolytic stress, which appears to facilitate 
the subsequent clearance of selected parkin substrates via autophagy. 
 
Parkin was originally identified as a gene whose mutations result in autosomal 
recessive juvenile parkinsonism or ARJP (Kitada et al., 1998). This disease is 
characterized by early-onset parkinsonism in which patients manifests its 
symptoms before the age of 45. As ARJP arises from the loss of parkin 
function, this suggests that functional parkin plays a neuroprotective role. 
Indeed, numerous studies have shown that parkin protects against different 
cellular stresses (Feany and Pallanck, 2003) including those that lead to 
proteasome dysfunction (Petrucelli et al., 2002; Tsai et al., 2003). However, 
the mechanism by which parkin protect against proteasome inhibition is 
unknown. In the first part of my project, I showed that proteasome impairment 
promotes parkin and Ubc13 interaction and concomitantly enhances parkin-
mediated K63-linked ubiquitination. This appears to facilitate aggregate 
formation and the subsequent clearance of parkin substrates by autophagy. 
Importantly, I showed that K63-linked ubiquitination protects cells against 
proteasome inhibition-induced cell toxicity. Taken together, I have identified a 
possible mechanism by which parkin protects cells against proteasome 
inhibition.  




Parkin is a unique multifunctional E3 ligase that mediates K48-, K63- 
polyubiquitination and mono-ubiquitination (Doss-Pepe et al., 2005; Hampe et 
al., 2006; Lim et al., 2005; Matsuda et al., 2006; Zhang et al., 2000). In this 
study, I showed that proteasome inhibition promotes parkin and Ubc13 
interaction (Fig. 3.6) which in turn leads to enhanced K63-linked 
ubiquitination in the Triton-X-100-insoluble fraction (Fig. 3.3). Notably, 
disease-associated parkin mutants, T240R, T415N and G430D, fail to enhance 
K63-linked ubiquitination in the presence of proteasome inhibition (Fig. 3.4), 
suggesting a possible role of K63-linked ubiquitination in cellular protection. 
Mechanistically, how proteasome inhibition promotes parkin and Ubc13 
interaction is unknown. Contrary to what Sha et. al. have demonstrated that  
PINK1 phosphorylation of parkin increases parkin and Ubc13 interaction (Sha 
et al., 2010), we did not observe any change in parkin phosphorylation status 
in the presence of proteasome inhibition (Fig. 3.9). This suggests that the 
phosphorylation status of parkin is unlikely to account for the increase in 
parkin and Ubc13 interaction during proteasome inhibition. Towards the end 
of this thesis completion, more evidences emerge that in the event of 
mitochondria depolarization, PINK1 phosphorylates parkin (Iguchi et al., 
2013; Kondapalli et al., 2012; Shiba-Fukushima et al., 2012). This was shown 
using phosphotag gel electrophoresis which retards the migration of 
phosphorylated proteins. Thus, with a more affirmative positive control and 
methodology, it would be interesting to examine the status of parkin 
phosphorylation in the presence of proteasome inhibition.  
 




Interestingly, the crystal structure of parkin was recently published by 4 
independent groups (Riley et al., 2013; Spratt et al., 2013; Trempe et al., 2013; 
Wauer and Komander, 2013). Collectively, these groups found that parkin 
contains 2 unexpected domain-domain interactions which results in parkin 
existing in a tightly folded conformation. The domain-domain interaction and 
its significances are as follows, (i) the interaction between RING0 and RING2 
occludes the active site (C431) on RING2 and (ii) the interaction of the linker 
region situated between IBR and RING2 with RING1 which blocks the E2-
binding site on RING1. These domain-domain interactions are of particular 
interest as they keep parkin in an auto-inhibited state. In accordance, our lab 
has previously shown that the region between parkin Ubl and RING1 domain 
inhibits parkin activity (Chew et al., 2011). That the interaction between 
Ubc13 and parkin (untagged or tagged) is enhanced in the presence of 
proteasome inhibition that concomitantly results in the elevation of K63-
linked ubiquitination would suggest that a change in parkin conformation has 
occurred in the presence of proteasome inhibition. Moreover, the engagement 
of parkin with Ubc13 seems to be important in stabilizing the E3 in its active 
form as in the presence of Ubc13-knockdown, the stability of parkin is 
compromised even in the presence of an impaired proteasome (Fig. 3.8A) 
 
As parkin protects against proteasome impairment, it is attractive to speculate 
that parkin is the only E3 capable of mediating enhanced K63-linked 
ubiquitination in the presence of proteasome inhibition. However, other E3 
ligases such as CHIP also exhibit enhanced Ubc13 interaction and enhanced 
K63-linked ubiquitination in the presence of proteasome impairment (Fig. 3.5, 




3.6). Consistent with this, the reduction in K63-linked ubiquitination in 
MG132-treated parkin null MEF compared to wild-type MEF is rather modest 
(Fig. 3.8B). Thus, it is highly possible that other E3 ligases capable of 
mediating K63-linked ubiquitination are also involved in this mechanism. 
Similarly, the observation of K63-polyubiquitination in Ubc13-knockout MEF 
suggests that besides Ubc13, there are other yet to be discovered E2s that are 
capable of mediating K63-linked ubiquitination.           
 
K63-linked ubiquitination is generally thought to be delinked from the 
proteasome although some studies indicate otherwise (Hofmann and Pickart, 
2001; Kim et al., 2007; Saeki et al., 2009). In this report, I provide further 
evidence that suggests that K63-linked ubiquitination is uncoupled from the 
proteasome. I showed that the increase in K63-linked ubiquitination under 
proteasome impairment is due to an increased in parkin and Ubc13 interaction 
instead of reduced proteasomal degradation of K63-linked ubiquitination. 
Supporting this, mass spectrometry data from others performed in cultured 
cells showed that all types of polyubiquitin chains increased in the presence of 
acute proteasome inhibition (45min) except those that are K63-linked 
(Jacobson et al., 2009; Xu et al., 2009). Significantly, a more chronic 
inhibition of 15h at a lower dose leads to an increase in K11-, K48- and K63- 
polyubiquitin chains (Jacobson et al., 2009), strongly suggesting that the 
increase in K63-linked ubiquitination is a cellular response instead of reduced 
proteasomal degradation.   
 




Notably, my results supports our lab's finding that K63-linked ubiquitination 
promotes aggregate formation (Tan et al., 2008b). Through the use of K63-
specific antibody, I showed that K63-linked ubiquitination resides 
predominantly or even elusively in the Trition-X-100- insoluble (P) fraction, a 
fraction where aggregates normally resides. Moreover, over-expression of 
parkin with synphilin-1, a substrate that our lab has demonstrated to be K63-
polyubiquitinated by parkin (Lim et al., 2005), promotes synphilin-1 
accumulation in the P fraction (Fig. 3.10). Supporting this, Olzmann et al. 
illustrated that parkin-mediated K63-linked ubiquitination of DJ-1 mutant 
L166P targets DJ-1 mutant to HDAC6 which then promotes its sequestration 
into aggresome (Olzmann et al., 2007). Aggresomes are thought to be the 
storage place for aggregated proteins which are subsequently cleared by 
autophagy. Moreover, K63-linked ubiquitination acts as a signal that recruits 
the autophagic machinery (Tan et al., 2008a; Tan et al., 2008b). Taken 
together, it suggests that parkin-mediated K63-linked ubiquitination in the 
presence of proteasome inhibition leads to aggregate formation which could 
then be cleared by autophagy. Indeed, synphilin-1 inclusions formed in the 
presence of over-expressed parkin and proteasome inhibition are amenable to 
autophagic clearance (Fig. 3.12). Importantly, this same phenomenon was 
observed when synphilin-1 was co-expressed with Ubc13/Uev1a but not 
UbcH7 (Fig. 3.12). Taken together, it suggests that enhanced parkin-mediated 
K63-linked ubiquitination in the presence of proteasome inhibition promotes 
inclusion formation which could be cleared by autophagy.          
 




Recently, Riley et. al. questioned the relevance of K63-linked ubiquitination in 
targeting misfolded proteins to the autophagic machinery (Riley et al., 2010). 
They hypothesized that if a specific ubiquitin chain targets its protein to the 
autophagic machinery, in the event that autophagy is impaired, that specific 
ubiquitin chain would increase in a significantly larger proportion compared to 
the rest of the ubiquitin chains. However, using quantitative mass 
spectrometry which measures the absolute amount of various ubiquitin chains, 
they observed an increase in all detectable ubiquitin chains (K6, K11, K48, 
K63) in roughly equal proportion in Atg5- and Atg7-knockout mice 
(autophagy deficient) compared to wild-type mice, suggesting that none of 
these ubiquitin chains target proteins to the autophagic machinery. They in 
turn proposed that the increase in all ubiquitin chains is an indirect 
consequence of p62 (an autophagy substrate) accumulation which activates the 
Nrf2-dependent stress response pathway that includes the transcription of 
proteins involved in ubiquitin metabolism. Although their study suggests that 
polyubiquitin chains are unlikely to be involved in selective autophagy, their 
study did not completely rule out the possibility that K63-linked ubiquitination 
may target proteins to the autophagic machinery. Interestingly, Hao et al. 
recently proposed that free K63-linked ubiquitin chains (not attached to 
substrates) could promote autophagy. They demonstrated that Poh1, a K63- 
specific deubiquitinating subunit in the proteasome which localizes to 
aggresomes, promotes the accumulation of free K63-linked chains by cleaving 
K63- polyubiquitin chains attached to substrates. These free K63-linked chains 
then activates HDAC6 which in turn activates the actin-myosin system thus 
promoting aggresome disintegration and autophagic clearance of the 




aggregates (Hao et al., 2013). This adds weight to our hypothesis that K63-
linked ubiquitination promotes aggresome clearance via autophagy.   
 
The enhancement of K63-linked ubiquitination under proteasome inhibition 
confers a protective effect. Using Ubc13-/- MEF that are presumably 
incapable of mediating K63-linked ubiquitination, I observed that Ubc13-/- 
MEF are more susceptible to proteasome inhibition-induced cell death 
compared to Wild-type MEF. Importantly, the reintroduction of Ubc13 but not 
UbcH7 into Ubc13-/- MEF rescues the cell from toxicity induced by MG132 
(Fig. 3.13). Significantly, proteasome inhibition induces an increase in K63-
linked ubiquitination in the Triton-X-100-insoluble fraction and this is 
inversely proportional to cell death (Fig. 3.13). Taken together, it suggests that 
K63-polyubiquitination enhances aggregate formation which provides 
protection against proteasome inhibition. Supporting this, recent studies 
suggest that aggregate formation is protective in nature. By over-expressing α-
synuclein and synphilin-1 in cultured cells in the presence of proteasome 
inhibitor, Tanaka et al. demonstrated that aggresome are more commonly 
found in non-apoptotic cells than in apoptotic cells (Tanaka et al., 2004). 
Similarly, using single live cell imaging, Arrasate et al. demonstrated that the 
formation of huntingtin inclusions enhances cell survival (Arrasate et al., 
2004).  
 
Interestingly, Winklhofer’s group showed that parkin-mediated K63-linked 
ubiquitination confers neuroprotection against kainate (excitotoxin) or 
rotenone (mitochondria complex I inhibitor)- induced toxicity by activating 




the NF-κB pathway (Henn et al., 2007). However, I did not observe a further 
increase in NF-κB activity in MG132-treated cells over-expressing parkin 
compared to untransfected cells that are similarly treated with MG132 (Fig. 
3.14). Consistently, parkin-mediated enhancement of K63-linked 
ubiquitination in the presence of proteasome inhibition was largely confined to 
the Triton-X-100- insoluble fraction, a fraction where aggregates normally 
resides in as oppose to the Triton-X-100- soluble fraction where NF-κB 
components normally resides in. This difference might be a result of different 
experimental approaches used or that parkin’s protective mechanism might 
differ between different cellular stressors.  
 
Finally, a recent paper by Paine et. al. that involve the use of K63 antibody 
demonstrated the presence of K63-positive inclusions in a mouse model that is 
deficient in proteasomal activity (Paine et al., 2009). However, in the same 
study, post-mortem analysis of PD brain with the same antibody showed that 
only a small percentage of Lewy bodies (LB) (~5%) are stained positive for 
K63-polyubiquitin chains. Similarly, mass spectrometry analysis of α-
synuclein extracted from LB revealed K48-linked ubiquitination but not K63-
linked ubiquitination (Anderson et al., 2006). These bring into question the 
relevance of parkin-mediated K63-linked ubiquitination in LB formation. A 
plausible explanation for such a discrepancy is that ubiquitin chains are largely 
dynamic in nature. Thus it is possible that K63-linked ubiquitin chains in LBs 
are progressively being removed by deubiquitinating enzymes. Supporting 
this, Hao et al. showed that proteasomal subunit Poh-1, which is frequently 
found in LB, preferentially cleave K63-linked ubiquitin chains. This promotes 




the accumulation of free K63-linked ubiquitin chains which activates HDAC6 
and promotes autophagic clearance of aggresome (Hao et al., 2013). In another 
study, Wang et al. demonstrated that the sequestration of mutant superoxide 
dismutase 1 (SOD1) into aggresome requires the activity of ataxin-3, a 
deubiquitinating enzyme which cleaves K63-linked ubiquitin chains on SOD1. 
Thus, K63-polyubiqutination could be modified at different phases of the 
selective autophagic machinery ie. formation of aggresome, clearance of 
aggresome, providing a plausible explanation for the lack of K63-linked 
ubiquitination in LBs.  
 
It is challenging to extrapolate the relevance of my findings with respect to 
parkin-knockout models due to its limitations. As parkin mutations results in 
autosomal recessive juvenile parkinsonism, it would ensue that parkin-
knockout mice would be a representative model to mimick Parkinson’s 
disease. However, to date, none of the parkin-knockout mice exhibit 
dopaminergic degeneration and motoric defects (Lim and Ng, 2009). They do 
instead display defects in dopamine handling, reduced mitochondria 
respiration, levels of mitochondria complexes and anti-oxidant capacity and an 
increase in reactive oxygen species-mediated damage (Goldberg et al., 2003; 
Itier et al., 2003; Palacino et al., 2004). It is though that the absence of 
phenotype might be due to the presence of a compensatory mechanism during 
development. This is illustrated by a recent study that generated conditional 
parkin-knockout mice in the ventral midbrain of 6 to 8 week-old mice. Age-
dependent dopaminergic neuron degeneration was observed in these mice 
although the motoric functions were not reported (Shin et al., 2011). Along the 




same lines, higher level of glutathione and DJ-1 (both having anti-oxidant 
property) were found in parkin-knockout midbrain neurons compared to wild-
type midbrain neurons and this was postulated to account for enhanced cell 
survival observed in parkin-knockout mice compared to wild-type mice in the 
presence of epoxomicin, a proteasome inhibitor (Casarejos et al., 2009). 
Interestingly, parkin-knockout Drosophila exhibits both dopaminergic 
degeneration and motoric defects, making it a more representative model of 
PD (Whitworth et al., 2005). However, proteasomal dysfunction has not been 
studied in parkin-knockout Drosophila and it would be highly interesting to 
examine my proposed protective mechanism in parkin-knockout Drosophila 
model.    
   
In summary, my results support our hypothesis that under conditions of 
proteasomal impairment, parkin is a key enzyme involved in the upregulation 
of K63-linked ubiquitination which directs misfolded proteins away from the 
proteasome into aggresome which are in turn cleared by autophagy. In doing 
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CHAPTER 4: CYTOSOLIC PINK1 STABILIZED BY NFΚB/TRAF6 
ACTIVATION VIA LYSINE 63-LINKED UBIQUITINATION 
PROMOTES NON-SELECTIVE MITOPHAGY 
 
4.1 Overview 
Two genes that are linked to recessive forms of PD, Parkin and PINK1, have 
recently been demonstrated to play a pivotal role in mitochondrial quality 
control. Specifically, these studies have shown that Parkin and PINK1 
collaborates to remove depolarized mitochondria from cells undergoing 
mitochondrial-related stress via mitophagy (Geisler et al., 2010; Matsuda et 
al., 2010; Narendra et al., 2008; Narendra et al., 2010b; Vives-Bauza et al., 
2010). According to the proposed model (Fig. 1.7 Chapter 1), a key initial 
event that occurs upon mitochondrial depolarization is the selective 
accumulation of PINK1 on the outer membrane of the damaged organelle, 
which enables the protein to recruit parkin to the outer mitochondrial 
membrane (OMM). This event is accompanied by parkin activation and the 
consequent parkin-mediated ubiquitination and degradation of several OMM 
proteins (Chan et al., 2011; Matsuda et al., 2010; Yoshii et al., 2011). 
Mitophagy induction then occurs, which likely involves parkin-mediated K63 
ubiquitination that will help recruit the autophagy adaptors HDAC6 and p62, 
subsequently leading to mitochondrial clustering around the peri-nucleus 
region (Geisler et al., 2010; Lee et al., 2010b). By virtue of their association 
with the autophagy process, the concerted actions of p62 and HDAC6 
Cytosolic PINK1 stabilized by NFκB/TRAF6 activation via K63-linked ubiquitination 
promotes non-selective mitophagy 
94 
 
presumably facilitate the final removal of damaged mitochondria by the 
lysosome.  
 
Under normal conditions, PINK1 accumulation on the OMM is prevented as 
the mitochondrial-targeting signal (MTS)-containing protein is rapidly 
imported through the sequential actions of the translocase of outer 
mitochondrial membrane (TOM) complex and the translocase of inner 
mitochondrial membrane (TIM) complex. During the importation process, the 
full length PINK1 is progressively modified by a series of mitochondrial 
proteases to a 53 kDa cleaved form (herein designated PINK1-53), which is 
rapidly degraded by the proteasome (Greene et al., 2012; Jin et al., 2010). 
Current evidence suggests that PINK1-53 is retrotranslocated to the cytosol 
and degraded through the N-end rule pathway via the actions of the UBR 
family of E3 ligases (UBR1, 2 and 4) (Yamano and Youle, 2013). Although 
these proteolytic events would ensure that PINK1 is kept at low levels under 
normal conditions (and as such to prevent mitophagy from occurring), it is 
intriguing at the same time to note that the cell has to go through such an 
elaborate process (i.e. to synthesize, import, cleave it twice, and degrade the 
protein) just to restrict its expression. It is attractive therefore, to speculate that 
the 53 kDa PINK1 protein might be stabilized under certain conditions to sub-
serve some cellular roles. Supporting this, accumulation of PINK-53, but not 
the full length protein, has been reported in the brains of both idiopathic and 
PINK1-related PD patients (Gandhi et al., 2006; Muqit et al., 2006). However, 
neither the mechanism stabilizing PINK1-53 nor its potential role in 
mitochondrial homeostasis was clarified.  
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Here, I present evidences showing that cytosolic PINK1-53 may be stabilized 
in the presence of K63-linked ubiquitination. Importantly, I have identified 
tumor necrosis factor receptor-associated factor 6 (TRAF6) as the E3 ligase 
responsible for the phenomenon and showed that TRAF-6-related NF-κB 
activation promotes the stability of PINK-53. Contrary to a recent report 
(Fedorowicz et al., 2013), I found that PINK1-53 does not inhibit parkin-
mediated mitophagy. Instead, it appears to trigger parkin translocation to 





4.2.1 Full length PINK1 and PINK1-53 are normally rapidly degraded 
 
Several studies have demonstrated that PINK1 is a labile protein whose 
expression is normally below the level of detection due to its rapid turnover 
(Takatori et al., 2008). Consistent with this, the levels of full length PINK1 or 
cleaved PINK1-53 are relatively low or absent under normal conditions even 
when full length is overexpressed in cells (Fig. 4.1A). However, when PINK1 
over-expressing cells are treated with proteasome inhibitors (MG132, PSI and 
lactacystin), the level of PINK1-53 but not the full length protein increased 
appreciably and becomes readily detectable (Fig. 4.1A). This phenomenon is 
not observed when these cells were treated with autophagy inhibitors (3MA 
and bafilomycin), which supports the finding by others that cleaved PINK1 is 
rapidly degraded by the proteasome.  
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Figure 4.1: PINK1-53 expression is selectively enhanced in the presence of 
proteasome inhibition. (A-B) Anti-PINK1 immunoblots of lysates prepared from 
control or PINK1-transfected HEK293 cells that are either untreated or treated with 
various compounds, as indicated. The blots above were stripped and reprobed with 
anti-actin as loading control.   
 
Conversely, in the presence of carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) treatment, a chemical uncoupler that collapses the mitochondrial 
membrane potential (ΔΨm) and as such prevents the importation of PINK1 
into the mitochondria, full length PINK1 but not PINK1-53 selectively 
accumulates (Fig. 4.1B). Together, these results demonstrate the highly labile 
nature of the PINK1 protein under normal growth conditions and support the 
current model of PINK1 processing. 
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4.2.2 K63-linked ubiquitination stabilizes PINK1-53 
To date, virtually all reports including my results above have demonstrated 
that appreciable amounts of PINK1-53 could only be observed in the presence 
of proteasome inhibition. In order for this fleeting species of PINK1 to fulfill a 
cellular role, it is reasonable to speculate that its expression might be 
promoted by certain hitherto unknown pathway that allows the protein to 
escape proteasome degradation. As an initial approach, especially given that 
proteins may be stabilized via K63 ubiquitin modification, I was naturally 
curious to examine whether this mode of ubiquitination could promote the 
stability of the otherwise short-lived PINK1-53 protein. For this purpose, full 
length untagged PINK1 was expressed in HEK293 cells in the absence or 
presence of HA-tagged wild type or mutant ubiquitin species that were 
mentioned in earlier chapters to either support (i.e. K63, K48R) or prevent (i.e. 
K48, K63R) K63 ubiquitin chain formation (Fig. 1.2; Chapter 1). Alongside 
these, MG132-treated PINK1-transfected cells were also included as a positive 
control. Consistent with the proteasome-independent role of K63-linked 
ubiquitination, I found that the level of PINK1-53 is selectively increased in 
the presence of K63 or K48R ubiquitin co-expression and to a comparable 
extent to that found in MG132-treated PINK1-transfected cells (Fig. 4.2A). 
Comparatively, the expression of PINK1-53 is dramatically reduced in 
transfected cells co-expressing wild type HA-ubiquitin and is hardly 
detectable in those co-expressing K48 or K63R ubiquitin (Fig. 4.2A). This 
suggests that upregulation of K63-linked ubiquitination can stabilize PINK1-
53.  
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Figure 4.2: PINK1-53 expression is enhanced under conditions where K63-
linked ubiquitination is promoted. (A) Representative anti-PINK1 and anti-HA 
immunoblots of cell lysates prepared from HEK293 cells transfected with untagged 
PINK1 and various HA-tagged ubiquitin species, as indicated. PINK1 over-
expressing cells treated with MG132 was included as a control. The blots above were 
stripped and reprobed with anti-actin as loading control. (B) Top, Representative anti-
PINK1 and anti-myc immunoblots of cell lysates prepared from PINK1 transfected 
cells co-expressing either myc-tagged Ubc13 or UbcH7. MG132-treated, PINK1 
over-expressing cells was included as a control. The blots above were stripped and 
reprobed with anti-actin as loading control.  Bottom, Bar graph showing the relative 
chymotrypsin-like proteasome activities of lysates prepared from PINK over-
expressing cells treated with MG132 or co-transfected with myc-tagged Ubc13. 
(**P<0.001 compared to column 1, Student’s t-test) These experiments were repeated 
at least three times with similar results. 
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To complement the findings above, the experiments were repeated with Ubc13 
(which specify K63-linked ubiquitination) and UbcH7 (for which no 
specificity for K63-linked chain has been reported) in place of the ubiquitin 
mutants. In agreement with the results above, the level of PINK1-53 is 
enhanced in the presence of Ubc13 but not UbcH7 co-expression (Fig. 4.2B), 
suggesting that endogenously-promoted K63-linked ubiquitination can 
similarly stabilize the cleaved PINK1 species. 
 
Given that ubiquitin modification may be reversed by the actions of 
deubiquitinating enzymes (DUBs), I surmised that the removal of K63-linked 
chains by DUBs specific for this ubiquitin topology could potentially 
counteract the stabilizing effect of Ubc13 over-expression on PINK1-53. To 
address this, PINK1 and Ubc13 were co-expressed together with ataxin 3, 
which has been reported to cleave K63-linked chains (Winborn et al., 2008). 
As controls, UCHL1 (a related ubiquitin hydrolase), SENP8 (a NEDD8-
specific deneddylase) or GFP were included in place of Ataxin 3. As expected, 
Ubc13-mediated enhancement of PINK1-53 level is significantly mitigated by 
ataxin 3 (Fig. 4.3). Moreover, this phenomenon is specific to ataxin 3 as none 
of the control overexpressed proteins affected Ubc13-mediated stabilization of 
PINK1-53. 
 
Collectively, the results above demonstrated that PINK1-53 (which is 
otherwise rapidly degraded normally) may be stabilized under conditions 
whereby K63-linked ubiquitination is promoted. Presumably, an E3 ligase 
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capable of promoting this form of ubiquitin modification is involved in the 
regulation of PINK1-53 stability. 
 
Figure 4.3: Ataxin-3, a deubiquitinase specific for K63-linked ubiquitin chain, 
mitigates Ubc13-mediated enhancement of PINK1-53. Representative anti-PINK1, 
anti-HA and anti-GFP immunoblots of cell lysates prepared from HEK293 cells over-
expressing untagged PINK1 and myc-tagged Ubc13 together with either GFP-tagged 
ataxin-3, HA-tagged UCHL1, HA-tagged SENP8 or GFP, as indicated. The blots 
above were stripped and reprobed with anti-actin as loading control. This experiment 
was repeated at least three times with similar results. 
   
4.2.3 Parkin expression does not stabilize PINK1-53 
As the E3 ligase parkin is known to be capable of mediating K63-linked 
ubiquitination and is furthermore intimately associated with PINK1 function, I 
naturally wondered whether its overexpression can affect the processing of 
PINK1 under normal culture condition (i.e. in the absence of MG132 or CCCP 
treatment). Interestingly, ectopically-expressed parkin appears to retard rather 
than promote the expression of the 53kD form of PINK1 (Fig. 4.4A). Instead, 
parkin expression enhances the accumulation of full length PINK1. Thus, 
parkin expression does not seem to promote PINK-53 stabilization. Given that 
parkin stabilizes full length PINK1, I next examined whether parkin 
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overexpression might instead counteract Ubc13-mediated enhancement of 
PINK1-53. I found that parkin, but not HHARI (an E3 which is closely related 
to parkin), effectively prevented the Ubc13-mediated phenomenon (Fig. 
4.4A), and presumably because PINK1-53 is not generated in the first place in 
the presence of over-expressed parkin.  
 
Notably, none of the PINK1 stabilization events recorded above (other than 
those occurring in MG132-treated cells) is associated with proteasomal 
dysfunction as the activity of the 20S proteasome is not significantly affected 
in the variously-transfected cells (Fig. 4.4B).    
 
Figure 4.4: Parkin expression does not stabilize PINK-53. (A) Representative anti-
PINK1, anti-myc, anti-FLAG and anti-HA immunoblots of cell lysates prepared from 
HEK293 cells over-expressing PINK1 together with myc-tagged Ubc13 or FLAG-
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tagged parkin alone or with myc-tagged Ubc13, as indicated. The above blots were 
stripped and reprobed with actin as control. (B) Bar graph showing the relative 
chymotrypsin-like proteasome activities of lysates prepared from PINK over-
expressing cells co-transfected with various E2s and E3s, as indicated. (**P<0.001 
compared to column 1, Student’s t-test) These experiments were repeated at least 
three times with similar results. 
 
 
4.2.4 TRAF6 expression stabilizes PINK1-53 in a specific manner 
Since parkin apparently does not promote the stabilization of PINK1-53, I was 
curious to find out which E3 could do the job. To elucidate the E3 member 
involved in PINK1-53 stabilization, a number of candidate E3 members whose 
activity is associated with K63-linked ubiquitination (Table 2; Chapter 1) 
and/or mitochondrial function were selected. These include TRAF6, UCHL1, 
CHIP, Mulan, RNF-11 and RNF-144B. Among these, only TRAF6 
overexpression could apparently enhance the level of PINK1-53, although the 
E3 ligase also promoted the accumulation of full length PINK1 but to a lesser 
extent than parkin (Fig. 4.5A).  
 
Figure 4.5: TRAF6 expression stabilizes PINK1-53. (A-B) Representative anti-
PINK1, anti-FLAG and anti-myc immunoblots of cell lysates prepared from PINK1 
over-expressed HEK293 cells co-transfected with various E3 ligases, as indicated. As 
a control, PINK1 over-expressed cells were either treated with MG132 or co-
transfected with Ubc13. * denotes non-specific bands. The above blots were stripped 
and reprobed with actin as control. These experiments were repeated at least three 
times with similar results. 
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Further analysis of TRAF6-mediated PINK1 stabilization via subcellular 
fractionation revealed that TRAF6 stabilizes PINK1-53 both in the cytosolic 
and mitochondrial fractions in a manner that is similar to that brought about by 
MG132 treatment and Ubc13 overexpression (Fig. 4.6A). That the 
mitochondrial marker Tom-20 partitioned virtually exclusively to the 
mitochondrial fraction suggests that the subcellular fractionation, albeit crude, 
was sufficiently pure to distinguish between the cytosolic and mitochondrial 
fractions. Consistent with this, confocal microscopy analysis of these cells 
showed that PINK1 is localized to both the cytosol and mitochondria in 
TRAF6 and Ubc13 over-expressing cells (Fig. 4.6B). 
 
While it may appear strange to note the enhancement of PINK1-53 level in the 
mitochondria in the presence of TRAF6 (when it should in theory be 
predominantly cytosolic), it is possible that the buildup of PINK1-53 in the 
cytosol may impede the retrotranslocation of freshly cleaved mitochondrial 
PINK1-53 into the cytosol (particularly when this species of PINK1 still 
retains a portion of the transmembrane region), although this remains to be 
proven. 
Cytosolic PINK1 stabilized by NFκB/TRAF6 activation via K63-linked ubiquitination 




Figure 4.6: TRAF6 expression stabilizes PINK1 in both cytosolic and 
mitochondrial fractions. (A) Representative anti-PINK1 and anti-myc immunoblots 
of cytosolic and mitochondrial fractions prepared from HEK293 cells over-expressing 
untagged PINK1 alone or co-expressed with myc-tagged Ubc13 or TRAF6 or treated 
with MG132. Anti-tom20 was included as a mitochondria marker. These experiments 
were repeated at least three times with similar results. (B) Representative confocal 
images of HEK293 cells over-expressing untagged PINK1 with either myc-tagged 
Ubc13 or myc-tagged TRAF6 immunostained with anti-myc (green), anti-PINK1 
(red) and anti-Tim23 (mitochondria marker) (purple). Arrows in merged images show 
PINK1 co-localization with mitochondria. These experiments were repeated at least 
three times with similar results.    
    
 
4.2.5 NF-κB pathway stabilizes PINK1-53  
Notwithstanding the above, the involvement of TRAF6 as a regulator of 
PINK1 stability begs the curiosity on whether NF-κB signaling activation 
might be relevant here (given that TRAF6 is a key activator of the NF-κB 
pathway). To address this, PINK1 over-expressing cells were treated with 
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TNFα and PMA, both of which are known to activate the NF-κB pathway. 
Indeed, an NF-κB assay confirmed the efficacy of these compounds in 
activating the pathway (Fig. 4.7A). Moreover, NF-κB p65 subunit translocates 
to the nucleus following TNFα and PMA treatment (Fig. 4.7B)  As suspected, 
both TNFα and PMA treatment results in the stabilization of PINK1-53 (Fig. 




Figure 4.7: Pharmacological activation of the NF-κB pathway stabilizes PINK1-
53. (A) Bar graph showing the relative fold difference in luminescence detected in the 
media of HEK293 cells treated with PMA, TNFα or DMSO compared to untreated 
cells. (*P<0.05, 
#
P=0.05 compared to column 1, Student’s t-test) (B) Representative 
confocal images of HEK293 cells treated with PMA, TNFα or DMSO immunostained 
with anti-p65 (red). Note the presence of p65 staining in the nucleus of PMA- and 
TNFα-treated cells. (C) Representative anti-PINK1 immunoblot of cell lysates 
prepared from PINK1 over-expressed HEK293 cells treated with PMA or TNFα. 
DMSO was included as a vehicle control. The above blot was stripped and reprobed 
with actin as loading control. This experiment was repeated at least three times with 
similar results. (D) Bar graph showing the relative chymotrypsin-like proteasome 
activities of lysates prepared from PINK over-expressing cells treated with PMA, 
TNFα or DMSO. All experiments were repeated at least 3 times with similar results, 
except B & D which were done once. Figure C was kindly provided by Doreen Chua. 
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In the canonical pathway, the NF-κB-related transcription factors are bound 
and inhibited by IκB proteins. Activators of the pathway induce the activation 
of the IKK complex (comprising of three members, i.e. IKKα, IKKβ and 
NEMO) that is responsible for the phosphorylation of IκBα at S32 and S36 
and its subsequent proteasomal degradation via ubiquitination (Fig. 4.8A). To 
further dissect the role of the pathway in stabilizing PINK1-53, PINK1 was 
co-expressed in the presence of wild type IKKβ, which promotes NF-κB 
signaling. Alongside this, an inactive IKKβ mutant (K44M) and a 
constitutively active counterpart (S177E/S181E) were included as controls. In 
the presence of wild type or S177E/S181E IKKβ  co-expression, PINK1-53 is 
stabilized to a comparable extent to that brought about by TRAF6 (Fig. 4.8B). 
This stabilization effect is abolished when wild type IKKβ is substituted by 
the inactive K44M mutant (Fig. 4.8B). Along the same line of investigations, 
PINK1 was co-expressed with wild type IκBα along with its dominant-
negative (S32A/S36A) mutant, both of which are expected to repress NF-κB 
activation. As anticipated, neither of the IκBα species leads to appreciable 
stabilization of PINK1-53 (Fig. 4.8C). Moreover, both wild type and mutant 
IκBα (along with the IKKβ K44M mutant) are able to block TNFα-mediated 
enhancement of PINK1-53 level (Fig. 4.8D). Thus, the negative effects of 
IκBα need to be repressed in order for PINK1-53 stabilization to occur. The 
importance of this is further illustrated by the ability of the constitutively 
active S177E/S181E IKKβ mutant to promote the expression of PINK1-53 in 
the presence of wild type IκBα but not the dominant-negative species (Fig. 
4.8C).  
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Further, to exclude that the stabilization of PINK1-53 seen may be due to the 
indirect effects of these mutants on the proteasome, a 20S proteasome assay 
was performed, which showed that none of the mutants used significantly 
affected its activity (Fig. 4.8E). 
 
Figure 4.8: Genetic activation of the NF-κB pathway stabilizes PINK1-53. (A) 
Schematic diagram illustrating the main players involved in the activation of the NF-
κB pathway. (B) Representative anti-PINK1, anti-FLAG and anti-myc immunoblots 
of cell lysates prepared from HEK293 cell over-expressing untagged PINK1 alone or 
with various FLAG-tagged IKKβ constructs or myc-tagged TRAF6, as indicated. (C) 
Representative anti-PINK1, anti-FLAG and anti-HA immunoblots of cell lysates 
prepared from HEK293 cells over-expressing untagged PINK1 with either HA-tagged 
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WT IκBα or mutant IκBα in the absence or presence of FLAG-tagged S177/181E 
IKKβ, as indicated. (D) Representative anti-PINK1, anti-myc immunoblots of cell 
lysates prepared from TNFα-treated HEK293 cells over-expressing untagged PINK1 
with either K44M IKKβ, WT IκBα or mutant IκBα.  The blots above were stripped 
and reprobed with actin as a loading control. (E) Bar graph showing the relative 
chymotrypsin-like proteasome activities of lysates prepared from cells over-
expressing PINK1 with various IKKβ and IκBα constructs, as indicated. These 
experiments were repeated at least two times with similar results. 
 
4.2.6 NF-κB activation-mediated PINK1-53 stabilization may be reversed 
by A20, DUB that cleaves K63-linked ubiquitin chains 
Taking the above and earlier findings together, one would assume that 
TRAF6/NF-κB signaling-mediated stabilization of PINK1 involves K63-
linked ubiquitination. To confirm this, I examined whether A20, which 
negatively regulates the NF-κB signaling pathway by virtue of its ability to 
cleave K63-linked chains from TRAF6 and RIP1, can influence PINK1-53 
stabilization by the pathway. Consistent with results above, I found that the 
stability of PINK1-53 is significantly reduced in TNFα-treated PINK1-
expressing cells in the presence of A20 co-expression (Fig. 4.9A). 
Surprisingly, the same is not observed in TRAF6 over-expressing cells. 
However, this could be due to the level of TRAF6 (by virtue of its 
overexpression) being overwhelming high in these cells for A20 to make a 
difference. Indeed, when the dose of A20 was increased in relation to TRAF6 
in transfected cells, I recorded a dose-dependent decrease in the level of 
PINK1-53 that is mediated by A20 in the presence of TRAF6 (Fig. 4.9B). 
These results collectively strongly demonstrated that the NF-κB pathway is a 
major regulator of the stability of PINK1-53 and that K63-linked 
ubiquitination is required for the phenomenon to occur.  
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Figure 4.9: A20, a deubiquitinase specific for K63-linked ubiquitin chain, 
mitigates NF-κB-mediated enhancement of PINK1-53. (A) Left, Representative 
anti-PINK1 and anti-GFP immunoblots of cell lysates prepared from TNFα-treated 
HEK293 cells transfected with untagged PINK1 alone or with GFP-tagged A20. 
Right, Same as left except that TNFα-treatment was replaced by myc-tagged TRAF6 
transfection. (B) Same as B right, except that the cells were transfected with 
increasing amount of A20. The blots above were stripped and reprobed with actin as a 
loading control. These experiments were repeated at least two times with similar 
results. 
 
Thus, a species of PINK1 that is otherwise rapidly degraded under normal 
conditions may become available to the cell (for whatever reasons) in the 
presence of a major cell signaling pathway. 
 
4.2.7 Generation and characterization of PINK1-53 mutants 
To facilitate the investigation of the potential cellular role of PINK1-53, a 
PINK1 truncated mutant that is devoid of the N-terminus 104 residue (104) 
was generated. This mutant, which mimics PINK1-53, contains a methionine 
(instead of phenylalanine) residue at its extreme N-terminus region and is thus 
expected to escape degradation by the proteasome via the N-rule pathway 
(which otherwise targets PINK1 F104 as the destabilizing residue to promote 
the degradation of PINK1-53) (Deas et al., 2011; Yamano and Youle, 2013). 
Anti-PINK1 immunoblotting of lysates prepared from PINK1104 transfected 
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cells revealed an intense band that corresponds to PINK1-53 (Fig. 4.10A). The 
clear abundance of the PINK1104 at steady state indicates that it is not 
rapidly degraded by the proteasome. Consistent with the predicted cytosolic 
nature of this PINK1 mutant that is truncated of its mitochondrial targeting 
sequence and much of its transmembrane region, PINK1104 distributes 
uniformly in the cytosol (Fig. 4.10B). 
 
Figure 4.10: Characterization of PINK1∆104. (A)Left, Anti-PINK1 immunoblot of 
cell lysates prepared from HEK293 cells transfected with either vector, untagged 
PINK1 or untagged PINK1∆104. Right, Schematic diagram showing the domains 
present in WT PINK1 and PINK1∆104. (B) Representative confocal images of 
HEK293 cells over-expressing untagged PINK1∆104 immunostained with anti-
PINK1 (green) and anti-Tim23 (mitochondria marker) (red). Note that PINK1∆104 
does not colocalize with Tim23. These figures are kindly contributed by Doreen 
Chua. 
 
4.2.8 Cytosolic PINK1-53 reported to inhibit mitophagy, but PINK1104 
expression does not compromise the process 
Interestingly, during the course of my investigation, a study published very 
recently by Fedorowicz et al suggests that cytosolic cleaved PINK1 (i.e. 
PINK1-53) represses parkin translocation to mitochondria and consequently 
inhibits mitophagy (Fedorowicz et al., 2013). Taking this finding together with 
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my data above, it is attractive to suggest that TRAF6/NF-κB activation may 
potentially counteract mitophagy through the promotion of PINK1-53 
expression. As an initial approach to examine this, the effects of PINK1104 
(which mimics PINK1-53) on parkin-mediated mitophagy was investigated.  
 
For this purpose, I first reproduced the mitophagy assay in the lab using the 
widely-used CCCP-treated HeLa cells stably expressing GFP-parkin system as 
a model (Note that native HeLa cells are otherwise deficient in parkin 
expression). Upon CCCP treatment, GFP-parkin begins to co-aggregate with 
Tom-20-stained mitochondria. As per the proposed model of parkin/PINK1-
mediated mitophagy, the CCCP-damaged mitochondria decorated with GFP-
parkin progressively move towards the peri-nucleus region to form “mito-
aggresomes”, which was evident from 2h post CCCP treatment onwards and 
particularly prominent at 8h post CCCP treatment (Fig. 4.11). From 16h post-
CCCP onwards, these structures started disappearing following mitophagy 
induction, which more or less was completed by 24h post CCCP treatment 
(Fig. 4.11). Comparatively, the localization of GFP-parkin and Tom-20-
positive mitochondria remain unaffected in control cells treated with DMSO 
for the same length of time (Fig. 4.11). 
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Figure 4.11: CCCP treatment of GFP-parkin HeLa cells induces the formation 
of mito-aggresome and the clearance of mitochondria. Representative confocal 
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images of HeLa cells stably expressing GFP-parkin (green) treated with CCCP for 
various time points. The cells were immunostained with anti-Tom20, a mitochondrial 
marker (red). Note the translocation of GFP-parkin to the mitochondria and the 
formation of mito-aggresome at 2h and the absence of mitochondria at 16h.    
  
 
Having established the mitophagy assay (which is the same one used by 
Fedorowicz et al), I next examined the effects of overexpressing PINK1104 
on the process, with the assumption based on the study reported by 
Fedorowicz et al that this form of PINK1 will retard the clearance of damaged 
mitochondria induced by CCCP treatment. Two time points post-CCCP 
treatment were chosen to reflect the two key aspects of the mitophagy process, 
i.e. co-aggregation of parkin with mitochondria and clearance of parkin/Tim-
23-positive mitochondria at 4h and 24h post-CCCP treatment respectively. 
Surprisingly, in the presence of PINK1104 expression, neither the co-
aggregation of parkin with mitochondria nor the subsequent clearance of these 
structures was affected (Fig. 4.12A). 
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Figure 4.12: PINK1104 expression does not compromise mitophagy (A) 
Representative confocal images of GFP-parkin HeLa cells transiently transfected with 
untagged PINK1104 treated with CCCP for 4h or 24h. The cells were 
immunostained with anti-PINK1 (red) and anti-Tim23, a mitochondrial marker 
(white). Outline denotes PINK1104 transfected cells with mitochondria clearance. 
(B) Representative confocal images of HEK293 cells transiently transfected with 
untagged PINK1104 and GFP-tagged parkin treated with CCCP for 24h. The cells 
were immunostained with anti-PINK1 (white) and anti-Tim23, a mitochondrial 
marker (red). Outlines denote co-transfected cells with mitochondria clearance. These 
experiments were repeated at least three times with similar results. Figure B was 
kindly provided by Doreen Chua.  
 
The above experiment was repeated in HEK293 cells co-transfected with 
parkin and PINK1104. Again, I failed to observe any effects of PINK1104 
on CCCP-induced mitophagy (Fig. 4.12B). Thus, contrary to what Fedorowicz 
et al has recently reported, PINK1-53 expression does not appear to have a 
negative effect over CCCP-induced mitophagy. 
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4.2.9 PINK1104 expression promotes parkin co-aggregation with 
mitochondria in the absence of apparent mitochondrial depolarization 
Curiously, in DMSO-treated control PINK1104 over-expressing HeLa cells 
(stably expressing GFP-parkin), GFP-parkin tends to be clustered with 
mitochondria at the perinucleus region at 4h post treatment (Fig. 4.13A). 
Quantification analysis revealed that more than 80% of GFP-parkin cells 
transfected with PINK1104 exhibit this feature of parkin-mitochondria co-
aggregation (Fig. 4.13B). At 24h post-DMSO treatment, a significant number 
of PINK1104 transfected cells contain abnormal mitochondria (ie. 
aggregated, reduced, cleared) as compared to untransfected cells. Importantly, 
the clearance of mitochondria is significantly enhanced in PINK1104-
expressing cells (Fig. 4.13A, B), suggesting the PINK1104 promotes 
mitophagy.  
 
It is possible that PINK1104-transfected cells may result in mitochondrial 
depolarization that leads to the recruitment of parkin to the organelle. To 
exclude this trivial possibility, I repeated the above experiment in the presence 
of mitotracker-RED, a red-fluorescent dye that stains mitochondria in live 
cells and its accumulation is dependent upon membrane potential. Due to a 
technical limitation (maximum 4 lasers available), cells exhibiting GFP-parkin 
localization on the mitochondria are taken to be PINK1104 transfected. 
Interestingly, GFP-parkin co-aggregated with mitotracker-RED-positive 
mitochondria in the presence of PINK1104 co-expression (Fig. 4.13C), 
suggesting that PINK1104 can promote the translocation of parkin to 
apparently normal mitochondria. 
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Figure 4.13: PINK1104 expression promotes parkin co-aggregation with 
mitochondria and subsequent mitophagy in the absence of apparent 
mitochondrial depolarization. (A) Representative confocal images of GFP-parkin 
HeLa cells transiently transfected with untagged PINK1104 treated with vehicle 
control DMSO for 4h or 24h. The cells were immunostained with anti-PINK1 (red) 
and anti-Tim23, a mitochondrial marker (purple). Outline denotes PINK1104 
transfected cells with mitochondria clearance. (B) Left, Bar graph showing the 
percentage of cells with GFP-parkin colocalization with mitochondria 4h post-DMSO 
treatment, as determined from confocal images. (**P<0.01, PINK1104 compared to 
untransfected cells (-), Student’s t-test) Right, Bar graph illustrating the percentage of 
cells with the indicted mitochondria network, as determined from confocal images. 
(*P<0.05, **P<0.01, Student’s t-test) N, Normal; A, Aggregated; R, Reduced; C, 
Cleared. At least 50 cells each from 3 independent experiments were counted for both 
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bar graphs. Bottom, Anti-Tim23 (purple) confocal images that illustrate the different 
types of mitochondria network scored. (C) Representative confocal images of GFP-
parkin HeLa cells transiently transfected with vector or untagged PINK1104 treated 
with DMSO for 4h. Mitotracker-RED was added 2h into DMSO treatment. Cells 
were stained with anti-Tim23 (purple). Note: GFP-parkin colocalization with mito-
aggresome was only observed with PINK1104 expression. Importantly these mito-
aggresomes are mitotracker-positive suggesting that the mitochondria are healthy 
mitochondria.   
 
To extend this finding, GFP-parkin was co-expressed with wild type or 
PINK1104 in HEK293 cells again in the absence of CCCP treatment. In 
HEK293 cells over-expressing GFP-parkin alone, the GFP signal was 
uniformly distributed in the cytosol. However, in the presence of wild type or 
PINK1104, GFP-parkin becomes aggregated at the perinuclear region and 
colocalized with mito-aggresomes (Fig. 4.14A).  
 
Consistent with this change in parkin localization, subcellular fractionation 
revealed a shift in parkin signal to the detergent-insoluble fraction when the 
protein was co-expressed with either forms of PINK1 (Fig. 4.14B).  
 
It would thus appear that the build-up of PINK1 in the cytosol promotes 
parkin-mitochondrial co-aggregation in the apparent absence of mitochondrial 
depolarization. 
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Figure 4.14: PINK1104 expression promotes parkin co-aggregation with 
mitochondria in HEK293 cells (A) Representative confocal images of HEK293 
cells transiently transfected with GFP-parkin with either vector, wild-type PINK1 or 
untagged PINK1104. The cells were immunostained with anti-PINK1 (white) and 
anti-Tim23 (red). Yellow arrows indicate GFP-parkin colocalization with 
mitochondria aggregates. (B) Representative anti-GFP immunoblots of Triton-X-100- 
(S) and SDS- (P) soluble lysates prepared from HEK293 cells over-expressing GFP-
parkin with either vector, wild-type PINK1 (WT) or  untagged PINK1104 as 
indicated. The blots above were stripped and reprobed with anti-actin as loading 
control. These experiments were repeated at least twice with similar results. These 
figures were kindly provided by Doreen Chua.  
 
4.2.10 Pharmacological treatment of PINK1-expressing cells with NF-kB 
activators promotes mitochondrial clearance 
As PINK1104 (which mimics PINK1-53) mediates parkin co-aggregation 
with mitochondria and mitophagy, I next examined whether NF-κB activation 
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which I have shown to stabilize PINK1-53, promotes the same phenomenon. 
HEK293 cells were transfected with wild-type PINK1 and treated with PMA 
for 24h. DMSO-treated cells were included as vehicle controls. Untransfected 
HEK293 cells treated with PMA showed no changes in the mitochondrial 
network as compared to DMSO-treated cells (Fig. 4.15A, C). Significantly, 
PMA treatment of PINK1-transfected cells results in an increase in reduced or 
cleared mitochondria compared to vehicle control (Fig. 4.15A, C). Taken 
together, this suggests that NF-κB-induced stabilization of PINK1-53 is able 
to induce mitochondrial clearance.     
 
Figure 4.15: Pharmacological treatment of PINK1-expressing cells with NF-kB 
activator promotes mitochondrial clearance (A-B) Bar graphs illustrating the 
percentage of (A) untransfected cells and (B) PINK1-transfected cells with normal or 
reduced/cleared mitochondrial network, as determined from confocal images. At least 
80 cells each from 3 independent experiments were counted for both bar graphs. (C) 
Representative confocal images of HEK293 cells transiently transfected with 
untagged PINK1 and treated with PMA or vehicle control, DMSO. The cells were 
immunostained with anti-PINK1 (red) and anti-Tim23 (green). * indicates PINK1-
transfected cells. Note the normal mitochondrial network in DMSO-treated cells (left) 
and reduced/cleared mitochondria network in PMA-treated, PINK1-transfected cells.   
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4.3 Discussion  
In summary, I present evidences in this chapter showing that K63-linked 
ubiquitination stabilizes the otherwise rapidly degraded PINK1-53. 
Importantly, I have identified that TRAF-6-related NF-κB activation promotes 
the stability of PINK1-53. Alongside this, I also attempted to elucidate the 
function of PINK1-53. Contrary to a recent report (Fedorowicz et al., 2013), I 
found that PINK1-53 does not inhibit parkin translocation to depolarized 
mitochondria and mitophagy. Instead, it appears to trigger parkin translocation 
to apparently normal mitochondria leading to non-selective mitophagy. 
 
PINK1, a serine/threonine kinase, is one of the causative genes of early onset 
autosomal recessive Parkinsonism (Valente et al., 2004). This strongly 
suggests that PINK1’s function is essential for neuronal survival. In this light, 
several groups have shown that PINK1 is able to protect against different 
cellular stressors including oxidative stress (Pridgeon et al., 2007). However, 
the mechanism by which it confers its protection is currently unknown. 
Furthermore, whether the cleaved form of PINK1, PINK1-53 is a functional 
protein or an unproductive by-product is poorly understood. I hypothesized 
that PINK1-53 plays a physiological role as it would otherwise be a waste of 
energy for the cell under normal conditions to synthesize PINK1, transport it 
into the inner membrane to be cleaved sequentially by mitochondrial 
processing peptidase (MPP) and presenilin-associated rhomboid-like protein 
(PARL), retrotranslocate it out of the mitochondria, only to ubiquitinate and 
degrade it via the proteasome. Supporting this, substantial nigra targeted 
adenoviral injection of full length PINK1 or truncated PINK1 that is deleted of 
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its N’ terminal 1-111 amino acid (resembles PINK1-53 that lacks N’ terminal 
1-104 amino acid) protects striatal neurons against a Parkinson’s disease-
associated toxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
(Haque et al., 2008). Moreover, using 2 PINK1 mutant constructs, P95A 
(which promotes the expression of full length PINK1) and F104A (which 
promotes the expression of PINK1-53), Deas et al. showed that PINK1 P95A 
mutant increases basal reactive oxygen species (ROS) level compared to WT 
PINK1 and PINK1 F104A mutant. Interestingly, WT PINK1 and PINK1 
F104A mutant exhibit similar ROS production profile under rotenone 
(mitochondrial complex 1 inhibitor) treatment, suggesting that PINK1-53 has 
a functional role similar to WT PINK1 (Deas et al., 2011). However, as 
PINK1-53 is rapidly degraded, there appears to be an unidentified mechanism 
that is able to stabilize PINK1-53 for it to perform its function, which was not 
clarified in the study by Deas et. al.   
 
In this study, I showed that K63-linked ubiquitination stabilizes PINK1-53 
independent of proteasomal activity. Using ubiquitin mutants (K63, K48R) or 
E2 (Ubc13) that supports K63-linked ubiquitination, I demonstrated that K63-
linked ubiquitination promotes the stabilization of PINK1-53 (Fig. 4.2A, B). 
Significantly, ataxin-3, a deubiquitinase that removes K63-linked 
ubiquitination, abrogates Ubc13-mediated stabilization of PINK1-53 (Fig. 
4.3). Taken together, these suggest that K63-linked ubiquitination stabilizes 
PINK1-53. It also further supports the notion that K63-polyubiquitination is 
uncoupled from the proteasome.  
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Importantly, I have identified a novel cellular pathway, the TRAF6-NF-κB 
pathway that could stabilize PINK1-53. By screening through 7 E3 ligases that 
have been shown to either mediate K63-linked ubiquitination (Parkin TRAF6, 
UCHL1, CHIP) or are present on the mitochondria (Mulan, RNF-11 and RNF-
144B), I identified TRAF6 as an E3 ligase that could stabilize PINK1-53 (Fig. 
4.5, 4.6). Curiously, full-length PINK1 also appears to be elevated in the 
presence of TRAF6 overexpression. Although this finding is in agreement 
with a recent report by Murata and colleagues who demonstrated during the 
course of my study that TRAF6 interacts with and stabilizes full length PINK1 
on depolarized mitochondria via K63-linked ubiquitination (Murata et al., 
2013), the accumulation of full length PINK1 should accordingly retard the 
formation of PINK1-53. Instead, I observed that TRAF6 expression also 
dramatically promotes the level of PINK1-53. One possible explanation is that 
some cells by virtue of TRAF6 overexpression may exhibit enhanced 
sensitivity towards mitochondrial stress that result in depolarization-induced 
PINK1 accumulation. Indeed, TRAF6 overexpression seems to promote 
significant cell death (data not shown).  
 
As TRAF6 is one of the key proteins involved in the NF-κB signaling 
pathway, I next examined whether the activation of the NF-κB pathway is able 
to stabilize PINK1-53. Using NF-κB pharmacological activators (PMA, 
TNFα) and constitutively active S177E/S181E IKKβ mutant, I showed that the 
activation of the NF-κB pathway results in an accumulation of full-length 
PINK1 and PINK1-53 similar to that mediated by TRAF6. This increase is 
also independent of proteasomal activity (Fig. 4.7C, 4.8). Interestingly, WT 
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IκBα (negatively regulate NF-κB signaling) reverses PINK1-53 accumulation 
in the presence of TNFα but not in the presence of S177E/S181E IKKβ. This 
difference might be due to a stronger and longer lasting stimulus mediated by 
S177E/S181E IKKβ than TNFα such that the constitutively active IKKβ is 
able to overcome the inhibitory effect of overexpressed IκBα. Notably, a 
dominant negative form of IκBα, S32A/S36A IκBα mutant, is able to abolish 
both TNFα- and S177E/S181E IKKβ-mediated stabilization of PINK1-53 (Fig 
4.8C, D), strongly suggesting that PINK1-53 stabilization is most likely 
downstream of IκBα. As the subsequent step involves the translocation of the 
NF-κB complex into the nucleus for transcription, PINK1-53 stabilization by 
NF-κB activation might involve NF-κB-mediated transcription of an unknown 
stabilizing factor. Importantly, this also implies that TRAF6 stabilization of 
PINK1-53 might be indirect, i.e. acting through the activation of NF-κB 
signaling pathway instead of by directly ubiquitinating and stabilizing PINK1-
53 via K63-polyubiquitination. That TRAF6 overexpression increases NF-κB 
activity is a well-known phenomenon that is also demonstrated above (Fig. 
3.14C). Moreover, I did not observe PINK1 polyubiquitination in the presence 
of TRAF6 (data not shown). Curiously, this is contrary to what Murata has 
reported where TRAF6 ubiquitinates full length PINK1 at Lys 433 and 
stabilizes it on depolarized mitochondria. Notably, Murata was studying the 
effects of TRAF6 along with sterile α and TIR motif containing 1(SARM) on 
full length PINK1 in CCCP-treated cells while I was looking at TRAF6 effects 
on PINK1-53 under normal conditions and these differences could account for 
such discrepancy. Nevertheless, I showed further that in the presence A20, a 
deubiquitinase that cleaves K63-linked chains in the NF-κB signaling 
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pathway, A20 reverses PINK1-53 stabilization (Fig. 4.9), suggesting that K63-
linked ubiquitination is still necessary for the stabilization of PINK1-53 
although this is presumably for the purpose of activating the NF-κB pathway 
rather than modifying PINK1-53 directly. 
 
Although the function of PINK1-53 remains unknown, I have shown that 
PINK1-53 do not inhibit parkin co-aggregation with mitochondria and 
mitophagy. This is contrary to a very recent report that showed that cytosolic 
PINK1 (Δ1-103 PINK1) inhibits the mitophagy process by binding to parkin 
and thus preventing parkin translocation to the mitochondria and its 
subsequent mitophagy (Fedorowicz et al., 2013) (Fig. 4.12). At this moment, I 
am unclear about what contributes to this discrepancy between the two studies. 
 
Notably, PINK1Δ104, which is cytosolic and resembles PINK1-53 formed in 
cells (Fig. 4.10), is able to induce parkin translocation to apparently healthy 
mitochondria and result in their clearance (Fig. 4.13, 4.14). This is unexpected 
as overexpression of similar PINK1 truncated constructs, which are localized 
in the cytosol, did not lead to parkin translocation to the mitochondria in both 
DMSO- or CCCP-treated cells (Geisler et al., 2010; Matsuda et al., 2010; 
Narendra et al., 2010b), suggesting that PINK1 localization on the 
mitochondria is required for parkin co-aggregation with the mitochondria, thus 
going against my observations. Surprising, Fedorowicz et al. also observed 
that truncated PINK1 (Δ1-103) promotes parkin co-aggregation with 
mitochondria and mitophagy in DMSO-treated cells although this runs 
contrary to their conclusion. They explained that this is possible as a fraction 
Cytosolic PINK1 stabilized by NFκB/TRAF6 activation via K63-linked ubiquitination 
promotes non-selective mitophagy 
125 
 
of the truncated PINK1 still associates with the mitochondria and thus able to 
stimulate parkin translocation to the mitochondria and mitophagy. However, 
this was not substantiated with further results, making it difficult to 
comprehend. Furthermore, if truncated PINK1 is indeed retained by the 
mitochondria, it should accordingly reside in the inner membrane, which will 
not result in parkin recruitment. Importantly, contrary to their explanation, I 
did not observe colocalization of PINK1Δ104 with mitochondria and in some 
cases even notice that regions of parkin-positive mito-aggregates are devoid of 
PINK1 staining (Fig. 4.10).  
 
Notwithstanding these gaps in knowledge, my current results showed that 
PINK1-53 is able to mediate parkin co-aggregation with mitochondria and 
subsequent mitophagy. To rule out the trivial reason that PINK1-53 might 
induce mitochondria depolarization which would lead to the above 
observations, I stained mitochondria with mito-tracker that labels healthy 
mitochondria. Parkin-labeled mito-aggregates colocalized with mito-tracker 
(Fig. 4.13C), suggesting that PINK1-53 mediates parkin translocation to 
healthy mitochondria that are subsequently cleared by mitophagy.     
 
Significantly, I showed that NF-κB pharmacological activator that stabilizes 
PINK1-53 promote mitochondria clearance in wild-type PINK1-transfected 
cells but not in untransfected cells (Fig. 4.15A, B). This suggests that NFκB-
induced accumulation of PINK1-53 (Fig. 4.7C) leads to the clearance of 
mitochondria. Curiously, although cells exhibit reduced mitochondria, the 
proportion of cells with cleared mitochondria is lesser than that observed in 
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GFP-parkin HeLa cells transfected with PINK1Δ104. This might be due to a 
difference in either the cell line used, the amount of PINK1-53 present in both 
situation or a slower kinetics of mitophagy in HEK cells. Thus more 
experiments have to be done to address this difference.   
 
Taken together, I have identified a major pathway in this study that could 
stabilize a form of PINK1 that is generally thought to be a fleeting species. 
Comparatively, this form of PINK1 is under-researched. My findings should 
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CHAPTER 5: GENERAL DISCUSSION AND CONCLUSIONS 
 
The overall objective of this thesis project was to understand the role of K63-
linked ubiquitination in protein and mitochondria homeostasis. On the 
completion of my project, I have made several important findings that helped 
refined our knowledge of the function of K63-linked ubiquitination in 
maintaining protein and mitochondria homeostasis.  
 
5.1 K63-linked ubiquitination in protein homeostasis 
In the first part of my thesis, I showed that in the event of proteolytic stress as 
a result of proteasome impairment, there is a significant enhancement of K63-
linked ubiquitination. Importantly, I have identified parkin as one of the key 
E3 ligases that mediates this proteolytic stress-related enhancement of K63-
polyubiquitination, which occurs as a result of its increased association with 
Ubc13. In addition, I showed that parkin-mediated K63-linked ubiquitination 
promotes inclusion clearance by autophagy. Moreover, using Ubc13-knockout 
MEFs as a model, I demonstrated that K63-linked ubiquitination confers 
protection against proteasome inhibition-induced cell toxicity. Taken together, 
these findings strongly support our hypothesis that in the presence of 
proteasome inhibition, parkin promotes K63-linked ubiquitination which 
serves to divert substrates away from the impaired proteasome to facilitate 
their aggregation and subsequent clearance by autophagy. By channeling 
substrates away from an overburdened proteasome to another degradation 
pathway (i.e. autophagy), parkin-mediated upregulation of K63-
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polyubiquitination thus serves to protect cells against proteolytic stress. A 
model illustrating the results that I have obtained is shown below (Fig. 5.1).  
  
 
Figure 5.1: Model of parkin-mediated polyubiquitination in normal and 
proteasome impaired cells. Under normal conditions, parkin mediates K48-linked 
ubiquitination on its substrates thus targeting it to the proteasome for degradation. In 
conditions that impair proteasome function, parkin preferentially mediates K63-
linked ubiquitination which results in aggresome formation and clearance by 
autophagy. This serves to protect cells against proteolytic stress and helps to maintain 
protein homeostasis.   
 
This model also helps in the understanding of how parkin, which functions as 
a wide spectrum neuroprotectant, protects cells against proteasome inhibition. 
At the same time, it also illustrates the versatility of parkin as an E3 ligase in 
mediating different types of ubiquitin chains under different conditions to 
maintain protein homeostasis. Although the exact mechanism that underlies 
the switch of parkin ubiquitination from one form to another remains 
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unclarified, based on what we currently know regarding the complexity of 
parkin's 3-dimensional conformation, it would most likely be due to either a 
post-translational modification and/or a change in parkin's conformation that 
enables parkin to recruit different E2s under different conditions.   
Notwithstanding this, my results here emphasize the importance of K63-linked 
ubiquitination in protecting cells against proteolytic stress.  
 
5.2 K63-linked ubiquitination in mitochondria homeostasis 
In my second chapter, I showed that K63-linked ubiquitination promotes the 
stabilization of PINK1-53, a cleaved form of PINK1 that is otherwise rapidly 
degraded. Comparatively, this truncated and apparently transient form of 
PINK1 is much less well characterized than its full length counterpart. 
Notably, I have identified a novel pathway, i.e. TRAF6/NF-κB signaling 
pathway, that stabilizes PINK1-53. Further, I showed that contrary to a recent 
report demonstrating that PINK1-53 may retard mitophagy by inhibiting 
parkin function (Fedorowicz et al., 2013), I found no evidence that PINK1-53 
functions in such a manner. Instead, I found that a PINK1-53 mimetic (i.e. 
PINK1Δ 104) induces parkin translocation to apparently normal mitochondria 
to promote non-selective mitophagy.  
 
Why a cell would mediate the clearance of otherwise normal mitochondria is 
bewildering. However, this is not unprecedented. For example, cancer cells 
within the tumor mass growing under hypoxic conditions are known to rid 
themselves of mitochondria to facilitate energy generation via glycolysis. 
Further, recent reports also demonstrated that in cells undergoing prolonged 
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hypoxia, mitophagy may help to reduce the level of ROS and thereby cell 
death and may as such represent an adaptive metabolic response (Zhang et al., 
2008). Based on these results, and the recognition that NF-κB signaling 
pathway, which stabilizes PINK1-53, is a stress response mechanism that is 
largely protective in nature, I propose that the removal of normal mitochondria 
via a PINK1-53-mediated mechanism could serve as a protective mechanism. 
It is well known that the mitochondria, being the site of the electron transport 
chain, are one of the main sources of oxidative stress. Hence, it is conceivable 
that the removal of mitochondria under conditions where ROS is elevated 
might serve as an attempt by the cell to mitigate the stress.  
 
That PINK1 processing is complex and importantly enables the protein to be 
localized to different regions of the cell has positioned it as an attractive 
candidate to serve different functions under changing cellular condition. A 
model that could be conceived from my above study and others is presented 
below   (Fig. 5.2). Firstly, under normal condition, PINK1 is rapidly cleaved in 
the mitochondria to PINK1-53 which is then retrotranslocated out of the 
mitochondria and degraded by the proteasome (Fig. 5.2, left). Under 
conditions that result in the depolarization of mitochondria, full-length PINK1 
accumulates on the outer membrane of the depolarized mitochondria and 
recruits parkin to the mitochondria (Fig. 5.2, middle) PINK1 then 
phosphorylates and activates parkin. Activated parkin then mediates the 
selective clearance of the damaged organelle. This process is termed "selective 
mitophagy" as the cell discriminate damaged mitochondria from healthy 
mitochondria in the removal process. Based on my results, I now propose a 
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form of mitophagy that could be considered as “non-selective mitophagy” (Fig 
5.2,Right). 
 
Figure 5.2: Proposed PINK1 function. A schematic diagram illustrating PINK1 
function in 3 scenarios. Refer to text for more details.  
 
In this model, NF-κB pathway is activated under conditions of increased 
oxidative stress, (Kratsovnik et al., 2005), which results in the stabilization of 
PINK1-53. PINK1-53 through an unknown mechanism then mediates the 
activation and translocation of parkin to the mitochondria. As PINK1-53 has 
an intact kinase domain, it is possible that PINK1-53 could phosphorylate 
parkin at S65 (and possibly other sites) to activate it. Activated parkin then 
mediates mitophagy in a depolarization-independent manner. The reduction of 
mitochondria in non-selective mitophagy might then serve as a protective 
mechanism to reduce reactive oxygen species production. With this model, 
one could appreciate that a single PINK1 protein with its various processed 
forms could serve as a sensor for at least 2 different cellular stresses and 
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mediate the clearance of mitochondria to achieve cellular and mitochondria 
homeostasis. Supporting this, PINK1-knockout drosophila and mice are more 
susceptible to oxidative stress and exhibit mitochondria defects (Exner et al., 
2007; Gautier et al., 2008). However, as PINK1-knockout would lead to an 
absence of both full length PINK1 and PINK1-53, one could not ascertain if 
the deficiency is due to the absence of full length PINK1, PINK1-53 or both. 
 
Admittedly, this non-selective mitophagy model is in its preliminary stage and 
more experiments have to be done to support or refine the model. For 
example, the relevance of oxidative stress in this model has to be verified 
amongst other gaps to be addressed.   
 
5.3 Implications of findings for Parkinson’s disease 
As parkin and PINK1, which are the key proteins investigated in my project, 
are causative genes in Parkinson’s disease (PD), I shall now briefly discuss the 
implications of my results in PD pathogenesis.   
 
Neurons being post-mitotic in nature have to be equipped with numerous 
stress response pathways to survive a lifetime of cellular insults. Accordingly, 
failure of such mechanisms due to age, environmental or genetic factors may 
result in neuronal cell death such as those occurring in PD. As the examination 
of post-mortem PD brain samples often reveals the presence of ubiquitin-
positive proteinaceous deposits that are also enriched with mitochondria 
complexes and components of the ubiquitin- proteasome system (UPS), 
autophagy system, and NF-kB signaling pathway (Wakabayashi et al., 2012), 
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the disruption of these cellular response processes are likely to be involved in 
the pathogenesis of PD.    
 
In this thesis, I proposed that K63-linked ubiquitination plays a role in two of 
the major stress response pathway in neurons. In the first chapter, I showed 
that parkin promotes K63-linked ubiquitination under proteolytic stress which 
then diverts misfolded proteins away from the malfunction proteasome to 
aggresome that are then cleared by autophagy. This serves as an attempt by the 
cell to eliminate misfolded proteins without exerting greater stress on the 
proteasome. This is highly relevant in PD as the activity and levels of 
proteasomal subunits were found to be reduced in the substantia nigra pars 
compacta (main region of neurodegeneration) of sporadic PB brain samples 
(McNaught and Jenner, 2001; Simunovic et al., 2009; St. P. McNaught et al., 
2003). Thus failure of this response mechanism (eg. parkin mutation) might 
lead to neuronal cell death. Notably, the clearance of these aggresome would 
then be dependent on the autophagic machinery. As aging is a risk factor for 
PD and autophagy has been shown to decrease with age (Keller et al., 2004), it 
appears that the autophagy pathway was sufficient for the cell to cope with the 
increase load initially. Intuitively, one would think that with a competent 
autophagy apparatus in place, protein aggregates should be cleared efficiently. 
However, with increased age, the autophagic machinery becomes 
overwhelmed and this presumably leads to the accumulation of aggregated 
proteins as seen in the presence of Lewy bodies in PD brains.   
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In the second chapter, I showed that TRAF6/NF-κB signaling pathway, which 
is dependent on K63-linked ubiquitination, stabilizes PINK1-53. Importantly, 
I showed that PINK1-53 promotes the clearance of normal mitochondria and 
suggest that this could be a cellular response by the cell to eliminate 
mitochondria as they are the main producer of reactive oxygen species in an 
attempt to reduce oxidative stress. This stress response mechanism is 
important in PD as increase oxidative stress levels was observed in PD brains 
(Alam et al., 1997). Moreover, substantia nigra neurons has a pro-oxidative 
environment as it has high oxygen consumption, high concentration of 
oxidizable substances including dopamine and polyunstaturated lipids and a 
low concentration of anti-oxidant species (Kidd, 2000). Although the 
relevance of oxidative stress on PINK1-53 was not investigated in this thesis, 
PINK1 has been shown to protect cells against oxidative stress though the 
species of PINK1 mediating the protection was not investigated (Pridgeon et 
al., 2007). Moreover, the accumulation of PINK1-53 in PD brains (Muqit et 
al., 2006) and its protection against PD-linked toxin, MPTP, in mice (Haque et 
al., 2008), suggests that PINK1-53 may be involved in one of the oxidative 
stress response pathway in PD.  
 
5.4 Future Work 
Notwithstanding the significant length of time that I have spent in pursuing the 
thesis objectives, I am cognizant that there remain gaps to be addressed and 
further questions to be answered. I have listed some of these below and the 
associated future work to be performed. 
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 Although I have found that parkin’s affinity with Ubc13 increases in 
the presence of proteasome inhibition, the exact mechanism behind this 
is unclear. Initial experiments with 2D-gel electrophoresis and 
immunoprecipitation suggest that parkin’s phosphorylation might not 
account for the increase in interaction. However, recent evidences in 
the mitophagy field by at least 3 independent groups suggest that 
parkin phosphorylation by PINK1 at S65 activates parkin, although 
whether the activation is linked to K48 or K63 ubiquitination was not 
clarified  (Iguchi et al., 2013; Kondapalli et al., 2012; Shiba-
Fukushima et al., 2012). In light of these findings, the role of parkin 
phosphorylation in relation to its increased interaction with Ubc13 
cannot be completely excluded at this moment. It would be interesting 
to examine the status of parkin phosphorylation in the presence of 
proteasome inhibition with phosphotag gel electrophoresis and to 
include a positive control which is parkin over-expressing cells treated 
with CCCP. It would also be desirable to re-examine this with parkin 
phospho-mimetics (e.g. S65E).  
 
 The protective role of K63-linked ubiquitination during proteolytic 
stress was demonstrated in Ubc13-knockout MEF cells. However, the 
relevance of parkin-mediated K63-linked ubiquitination was not 
investigated in this system. It would be interesting to investigate if 
parkin overexpression against an Ubc13 null background has any 
positive effects.    
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 Although I showed that the NF-κB pathway stabilizes PINK1-53, the 
exact mechanism behind it is poorly understood. Considering that a 
dominant negative form of IκBα is able to abolish NFκB-mediated 
stabilization of PINK1-53, the stabilization of PINK1-53 might involve 
NFκB-mediated transcription of an unknown stabilizing factor. This 
factor could stabilize PINK1-53 either by binding directly to it or by 
inhibiting the actions of UBR1, which mediates the degradation of 
PINK1-53 via the proteasome (Yamano and Youle, 2013). Future 
experiments should shed light on the need and identity of this factor. 
 
 The TRAF6/NF-κB pathway stabilizes both full-length PINK1 and 
PINK1-53. As full-length PINK1 accumulation is a result of 
mitochondrial membrane depolarization that impedes PINK1 import 
and thus the formation of PINK1-53, it is intriguing that both species 
are stabilized at the same time. Conceivably, it is possible that TRAF6 
overexpression or NF-κB activation might induce mitochondrial 
depolarization in some mitochondria thus leading to the accumulation 
of full length PINK1 on these mitochondria while also stabilizing 
PINK1-53. Thus mitochondrial membrane potential in these 
transfected cells needs to be examined more closely.    
 
 The observation that PINK1-53 mediates non-selective mitophagy 
raises the question regarding the functional relevance of such a 
phenomenon. I proposed that this occurs during increased reactive 
oxygen species levels and that the clearance of mitochondria helps to 
reduce oxidative stress. Thus, it is important to first examine the 
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effects of oxidative stress and other stressors on PINK1-53 
stabilization. Following that, the role of mitochondria clearance in the 
presence of selected stressors would be investigated.      
 
 Notably, the above studies were done in HEK293, SH-SY5Y and HeLa 
cells lines as these allow me to study the mechanism of K63-
polyubiquitination in both protein and mitochondria homeostasis. To 
further validate the relevance of K63-linked ubiquitination in PD, more 
ex vivo and in vivo experiments involving dopaminergic neurons have 
to be performed.   
 
5.5 Conclusions  
The objective of my project is to understand the role of K63-linked 
ubiquitination in protein and mitochondrial homeostasis. I believe that my 
findings in this thesis represent a significant contribution towards refining the 
role of K63-linked ubiquitination in both protein and mitochondrial 
homeostasis. To summarize, I have shown the following: 
 
  Parkin-mediated K63-linked ubiquitination is enhanced under 
conditions of proteasomal impairment. This is as a result of increased 
parkin’s affinity to Ubc13. Notably, parkin-mediated K63-
polyubiquitination promotes the formation of inclusions which are 
then cleared by autophagy. Importantly, I showed that K63-
polyubiquitination protects cells against proteolytic stress-induced cell 
toxicity. These results help to refine the protective role of K63-linked 
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ubiquitination in protein homeostasis and clarify the protective role of 
parkin under proteolytic stress.   
 
  TRAF6/NF-κB signaling pathway through K63-polyubiquitination 
promotes the stabilization of PINK1-53, a cleaved form of PINK1 that 
is otherwise rapidly degraded. This is a novel finding. Notably, I 
showed that contrary to recent report (Fedorowicz et al., 2013), 
PINK1-53 do not inhibit parkin translocation to depolarized 
mitochondria and mitophagy. Instead, it induces parkin translocation 
to apparently normal mitochondria and mitophagy. These results 
ascribe a new functional role of K63-linked ubiquitination in PINK1-
53 stability and its role in mitochondrial homeostasis.   
 
 
Taken together, my results presented in this thesis have helped deepen our 
understanding of the role of K63-polyubiquitination in maintaining both 
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